Poster Presentations

* Presenting Author

PP-MO-001 FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ANALYSIS OF ACTIVATED PLATELET INTEGRIN ALPHA IIB BETA 3 VARIANTS EXPRESSED IN HEK293 CELLS
R. E. Scharf, A. El Khattouti* (DE), V. R. Stoldt, M. Gyenes

PP-MO-002 MODULATION OF PLATELET ADHESION BY DIFFERENTIAL PHOSPHORYLATION OF MULTIPLE GLYCOPROTEIN IB ALPHA SERINE AND THREONINE RESIDUES
A. D. Munday* (US), R. A. Penkala, W. E. Thomas, J. A. Lopez

PP-MO-003 DO HUMAN PLATELETS HAVE A PERIMEMBRANE, EXTRACELLULAR CA2+ SOURCE WHICH CAN BE MOBILISED UPON THROMBIN STIMULATION?
A. G. S. Harper* (UK), S. O. Sage

PP-MO-004 PLATELET SURFACE BINDING ENHANCES IMMUNE COMPLEX-INDUCED PLATELET AGGREGATION
M. L. Hatfield, J. Meyer, L. Robles-Carillo, A. Amirkhosravi* (US), T. Meyer, J. Francis

PP-MO-005 FRACTALKINE PROMOTES PLATELET ACTIVATION AND VASCULAR DYSFUNCTION IN CHRONIC HEART FAILURE: A LINK TO IMPAIRED CLOPIDOGREL RESPONSIVENESS
A. Schaefer* (DE), C. Schulz, D. Fraccarollo, S. Massberg, J. Bauersachs

PP-MO-006 LIPID RAFTS REGULATE PAR-1 SIGNALING LEADING TO PLATELET ACTIVATION AND PLATELET-INDUCED MONOCYTE ACTIVATION
A. E. Schade* (US), E. Shick

PP-MO-007 INDUCTION OF INSULIN RESISTANCE BY ADIPOKINES IN HUMAN MEGAKARYOCYTES
A. J. Gerrits* (NL), E. Gitz, C. A. Koekman, F. L. Visseren, J. W. N. Akkerman

PP-MO-008 THE PLAQUE LIPID LYSOPHOSPHATIDIC ACID STIMULATES HUMAN MEGAKARYOCYTIC CELLS VIA THE LPA5 RECEPTOR
A. L. Khandoga* (DE), P. Goyal, W. Siess

PP-MO-009 BINDING OF PLASMA FACTOR XIII TO THROMBIN-RECEPTOR ACTIVATED HUMAN PLATELETS
B. Nagy* (HU), Z. Simon, Z. Bagoly, L. Muszbek, J. Kappelmayer

PP-MO-010 STREPTOCOCCUS PYOGENES BACTERIA INDUCE PLATELET ACTIVATION AND AGGREGATION VIA A FIBRINOGEN-DEPENDENT MECHANISM
C. Liu* (TW), Y. Chen, L. Chang

PP-MO-011 PLATELET KAINIC ACID RECEPTOR SIGNALING PROMOTES THROMBOSIS BY STIMULATING CYCLOOXYGENASE ACTIVATION IN A MAPK DEPENDENT MANNER
H. Sun, A. Swaim, C. N. Morrell* (US)

PP-MO-012 CD40L PRIMES PLATELETS AND ENHANCES AGONIST-INDUCED ACTIVATION AND AGGREGATION TROUGH CD40-MEDIATED SHAPE CHANGE AND FILOPODIA FORMATION
D. Yacoub* (CA), A. Hachem, J. F. Théorêt, M. Tabrizian, W. Mourad, Y. Merhi

PP-MO-013 HEMATOCRIT AND ERYTHROCYTE DEFORMABILITY AFFECT ADP PLATELET REACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES ON DUAL ANTIPLATELET THERAPY
E. Cecchi* (IT), R. Marcucci, R. Paniccia, B. Bandinelli, S. Valente, C. Giglioli, C. Lazzeri, G. Gensini, R. Abbate, L. Mannini

PP-MO-014 IDENTIFICATION OF G PROTEIN-COUPLED RECEPTORS (GPCRS) IN HUMAN PLATELETS BY GENE EXPRESSION PROFILING
A. Hansen, B. Spath, C. Bokemeyer, B. Eifrig, F. Langer* (DE)

PP-MO-015 THROMBOXANE AND PROSTACYCLIN BIOSYNTHESIS IN HEART FAILURE OF ISCHEMIC ORIGIN: EFFECTS OF DISEASE SEVERITY AND ASPIRIN TREATMENT
F. Santilli* (IT), G. Davi, S. Basili, S. Lattanzio, A. Cavoni, G. Guizzardi, L. de Feudis, G. Traisci, C. Pettinella, P. Minuz, A. Meneguzzi, G. Ciabattoni, C. Patrono

PP-MO-016 POSTPRANDIAL HYPERGLYCEMIA IS AN IMPORTANT DETERMINANT OF PLATELET ACTIVATION. EVIDENCE FROM BIOCHEMICAL MEASUREMENTS AND PHARMACOLOGICAL INTERVENTION WITH ACARBOSE
F. Santilli* (IT), G. Formoso, P. Sbraccia, M. Averna, R. Miccoli, P. di Fulvio, A. Ganci, N. Pulizzi, S. Lattanzio, G. Ciabattoni, A. Consoli, R. Lauro, C. Patrono, G. Davi

PP-MO-017 CROSS ACTIVATION OF PAR-1 AND -4 BY PAR-1 AND -4 AGONIST PEPTIDES
L. L. Dewar, Y. Song, S. J. Craven, F. A. Ofosu* (CA)

PP-MO-018 A NOVEL SINERGISM BETWEEN EPINEPHRINE AND ADP STIMULATES PROTEIN KINASE C AND RAP1B ACTIVATION
P. Lova, G. F. Guidetti* (IT), I. Canobbio, C. Balduini, M. Torti

PP-MO-019 INCREASED PLASMA PHOSPHOLIPID AND PLATELET MICROPARTICLES IN ACUTE STROKE
G. Gilmore* (AU), J. Thom, G. Hankey, J. Eikelboom, R. Baker

PP-MO-020 DO YOUNG PLATELETS HAVE AN ENHANCED CAPACITY TO EXPOSE PROCOAGULANT PHOSPHATIDYLSERINE (PS) UPON ACTIVATION?
M. L. Rand* (CA), H. Wang, K. W. Annie Bang, J. Freedman

PP-MO-021 PLATELET PAI-1 RELEASE IS DEPENDENT ON BOTH THROMBIN RECEPTOR PAR1 AND PAR4
M. Nylander* (SE), E. Löfgren, M. Grenegård, T. L. Lindahl

PP-MO-022 PROLACTIN DOES NOT AFFECT HUMAN PLATELET AGGREGATION OR SECRETION
A. Q. Reuwer, R. Nieuwland* (NL), I. Fernandez, V. Goffin, C. M. van Tiel, M. C. L. Schaap, R. Berckmans, J. J. P. Kastelein, M. Twickler

PP-MO-023 NITRIC OXIDE INDUCES VASODILATOR-STIMULATED PHOSPHOPROTEIN PHOSPHORYLATION BY PROTEIN KINASE G-DEPENDENT AND INDEPENDENT MECHANISMS: ROLE OF PROTEIN KINASE C
A. A. Aburima* (UK), R. Riba, K. M. Naseem

PP-MO-024 REGULATION OF COLLAGEN MEDIATED PLATELET ADHESION AND AGGREGATION UNDER CONDITIONS OF FLOW BY PROSTACYCLIN
A. Michno* (UK), W. Roberts, S. Homer-Vanniasinkam, K. M. Naseem

PP-MO-025 PLATELET-ACTIVE SUBSTANCES IN THE VENOM OF BOTHROPS MOOJENI SNAKE – AN EVALUATION USING WHOLE BLOOD AGGREGOMETRY
C. Demler, B. Buehler, A. M. Perchuc* (DE)

PP-MO-026 THE PLASMA MEMBRANE CALCIUM ATPASE REGULATES CALCIUM HOMEOSTASIS AND FUNCTION IN PLATELETS
A. B. Solomon* (UK), S. Jones, D. Sanz-Rosa, M. Emerson

PP-MO-027 PLATELET RECEPTORS AND SIGNAL TRANSDUCTION MECHANISMS INVOLVED IN ERYTHROCYTE-AMPLIFIED PLATELET REACTIVITY
A. Moscardo* (ES), J. Valles, M. A. Dasi, A. Latorre, M. T. Santos

PP-MO-028 CURCUMIN INHIBITS GPVI-MEDIATED PLATELET ACTIVATION BY INTERFERING WITH THE KINASE ACTIVITY OF SYK AND THE SUBSEQUENT ACTIVATION OF PLCGAMMA2
A. Mayanglambam* (US), J. L. Daniel, C. A. Dangelmaier, C. D. Reddy, D. Thomas, S. P. Kunapuli

PP-MO-029 HUMAN PLATELET GRANULE SECRETION INDUCED BY THROMBIN AND COLLAGEN IS DIFFERENTIALLY MODULATED BY INTEGRINS: PLATELET FUNCTION OF A PATIENT WITH LAD-1V/LAD-III SYNDROME
K. Jurk, A. S. Schulz, W. Friedrich, H. Schulze, H. Omran, R. Henschler, J. S. Scheele, B. E. Kehrel* (DE), B. Zieger

PP-MO-030 THE EXTRACELLULAR ADHERENCE PROTEIN (EAP) OF STAPHYLOCOCCUS AUREUS ACTIVATES PLATELETS VIA THE ATP-GATED P2X1 CATION CHANNEL AND FCGAMMA RIIA
S. Niemann, M. Hussain, S. Pohl, T. Schifferdecker, A. Schulte, A. Bertling, C. Heilmann, B. E. Kehrel* (DE)

PP-MO-031 THE FUNGAL METABOLITE GLIOTOXIN INHIBITS PLATELET FUNCTION IN VITRO
A. Bertling, S. Niemann, A. Uekötter, C. Lass-Flörl, C. von Eiff, B. E. Kehrel* (DE)

PP-MO-032 A STRUCTURAL BASIS FOR THE INHIBITION OF SRC-FAMILY KINASE ACTIVITY BY DIETARY FLAVONOIDS
B. Wright* (UK), J. A. Lovegrove, J. M. Gibbins

PP-MO-033 SEQUENCE DIFFERENCES IN THE N-TERMINAL REGION OF MOUSE GPIB? CHANGE PROTEASE SPECIFICITY AND PREVENT THROMBIN BINDING
C. Ravanat* (FR), V. Wurtz, C. Strassel, R. K. Andrews, S. Schuhler, C. Gachet, F. Lanza

PP-MO-034 PHOSPHOTYROSINE PROTEINS IN PLATELETS FROM PATIENTS WITH STICKY PLATELET SYNDROME
D. M. Fries* (BR), C. S. S. S. Silva, V. Oliveira, L. Lopes, F. E. V. Barros, V. Debbas, M. L. Santoro, E. A. D’Amico, T. J. C. Neiva, T. R. F. Rocha

PP-MO-035 EFFECT OF GLYCOPROTEIN IBALPHA CLUSTERING ON PLATELET CLEARANCE IN VIVO
D. E. van der Wal* (NL), S. Verhoef, J. W. N. Akkerman

PP-MO-036 ROLE OF GLYCOPROTEIN IBALPHA MOBILITY IN PLATELET FUNCTION
D. E. van der Wal* (NL), S. Verhoef, R. E. G. Schutgens, M. P. Peters, J. W. N. Akkerman

PP-MO-037 INTERRELATION BETWEEN PERIPHERAL PLATELET COUNT AND PLATELET ACTIVATION DURING AND AFTER LIVER SURGERY IN PIGS
A. H. Hussein, S. A. Kishta, E. A. A. Khaled* (EG)

PP-MO-038 EFFECT OF NYTROXYL AND NITRIC OXIDE ON THE OXIDATIVE STATUS IN NORMAL PLATELETS
E. Bermejo* (AR), M. F. Alberto, D. Saenz, S. Bari, M. A. Lazzari, R. Rosenstein

PP-MO-039 HUMAN FIBRINOGEN SUPPORTS NORMAL HEMOSTATIC FUNCTION IN A MOUSE PLATELET SYSTEM
E. S. Krystofiak* (US), J. A. Oliver

PP-MO-040 ACCURATE QUANTIFICATION OF MICROPARTICLES BY FLOW CYTOMETRY : IMPORTANT ISSUES
F. Mullier* (BE), J. M. Dogné, N. Bailly, Y. Cornet, S. Robert, B. Chatelain

PP-MO-041 A ROLE FOR ADAP IN REGULATING INTEGRIN ALPHA2BETA1 IN PLATELETS
G. E. Jarvis* (UK), S. Hamaia, D. Bihan, C. E. Rudd, R. W. Farndale

PP-MO-042 PLATELET PROTEIN DISULFIDE ISOMERASE IS RESTRICTED TO THE DENSE TUBULAR SYSTEM AND NOT ASSOCIATED WITH THE CELL SURFACE
H. E. van Nispen Tot Pannerden, S. M. van Dijk, V. Du, H. F. G. Heijnen* (NL)

PP-MO-043 REPLACEMENT OF PHE992 AND PHE993 WITH ALA IN THE INTEGRIN ALPHA IIB CYTOPLASMIC MOTIF CHANGES THE BINDING AFFINITY TO ITS INTERACTORS
M. Raab, R. Moriarty, L. Parthasarathi, S. Allen, N. Moran, H. Daxecker* (IE)

PP-MO-044 PROTEIN INTERACTIONS WITH THE INTEGRIN ALPHA REGULATORY MOTIF: A COMPARISON OF METHODS
H. Daxecker* (IE), M. Raab, R. J. Edwards, D. Murphy, A. Treumann, N. Moran

PP-MO-045 A FUNCTIONAL POOL OF P2Y12 RECEPTORS EXPOSED UPON PLATELET ACTIVATION PERSISTS IN MICE TREATED WITH HIGH DOSE CLOPIDOGREL, AND CAN BE BLOCKED BY ELINOGREL, A DIRECT ACTING, REVERSIBLE P2Y12 INHIBITOR
H. Haberstock-Debic* (US), P. Andre, S. M. Delaney, S. Mills, Y. Pak, D. R. Phillips, P. B. Conley

PP-MO-046 AMYLOID PRECURSOR PROTEIN PROTEOLYSIS IN HUMAN PLATELETS IS REGULATED BY CALMODULIN
I. Canobbio* (IT), S. Catricalà, L. Cipolla, C. Balduini, M. Torti

PP-MO-047 PLATELET ADHESION TO PROTEINS IN MICROPLATES: FROM EXPERIMENTAL RESEARCH TO CLINICAL EVALUATION OF PLATELET FUNCTION
A. C. Eriksson* (SE), P. A. Whiss

PP-MO-048 PLATELET ADHESION UNDER ARTERIAL FLOW CONDITIONS TO A VON WILLEBRAND FACTOR-BINDING PEPTIDE SEQUENCE PRESENT IN COLLAGEN III
B. D. Maddox* (UK), G. E. Jarvis, R. W. Farndale

PP-MO-049 DIFFERENT BINDING CHARACTERISTICS OF THE INTEGRIN ALPHA 2 BETA 1 DUE TO I-DOMAIN MUTATIONS
B. F. Iserbyt* (BE), S. Staelens, G. R. van de Walle, I. S. Salles, I. Pareyn, K. Vanhoorelbeke, H. Deckmyn

PP-MO-050 INFLUENCE OF THE NOVEL INTERACTORS SLAP-2 AND RHOGDI-α ON INTEGRIN α2β1 BINDING
B. F. Iserbyt* (BE), S. Katsutani, S. Staelens, N. Vandeputte, I. Pareyn, K. Vanhoorelbeke, H. Deckmyn

PP-MO-051 PLATELET GPIIB/IIIA SUPPORTS ADHESION TO A NOVEL STREPTOCOCCUS GORDONII SURFACE PROTEIN
C. Keane* (IE), H. Petersen, M. Vickerman, D. Cox, H. F. Jenkinson, S. W. Kerrigan

PP-MO-052 OESTROGENIC AND ANDROGENIC MODULATION OF ITGA2 PROMOTER ACTIVITY AND INTEGRIN ALPHA 2 EXPRESSION LEVEL
F. M. Al-Zahrani* (UK), M. E. Daly, P. R. Winship

PP-MO-053 PLATELET ASSOCIATED TISSUE FACTOR ENHANCES THROMBUS FORMATION ON THROMBOGENIC SURFACES
I. Lopez-Vilchez* (ES), A. M. Galan, F. Navalon, L. Brunso, P. Molina, M. Diaz-Ricart, G. Escolar

PP-MO-054 CD9 TETRASPANIN IS A REPRESSOR OF GPIIB-IIIA ACTIVATION
J. Kotha* (US), S. N. Hill, S. Grgurevich, S. Cholera, L. K. Jennings

PP-MO-055 INHIBITORY EFFECT OF QUERCETIN ON PLATELET SPREADING ON COLLAGEN AND FIBRINOGEN AND ON MULTIPLE PLATELET KINASES
L. Navarro-Núñez* (ES), M. Lozano, C. Martínez, V. Vicente, J. Castillo, J. Rivera

PP-MO-056 RELEASE OF PENTRAXIN-3 FROM ACTIVATED NEUTROPHIL MODULATES PLATELETNEUTROPHIL CROSS-TALK
N. Maugeri* (IT), R. Patrizia, D. Andrea, B. Barbara, C. Domenico, M. Attilio, M. Alberto, A. A. Manfredi

PP-MO-057 THE PECULIAR PLATELET BEHAVIOR IN THE ARABIAN CAMEL (CAMEL DROMEDARIUS)
A. M. Abdelgadir* (SA), A. K. Al Ghomlas, A. Al Haidari, M. F. Husain, J. White

PP-MO-058 STRATEGY FOR THE USE OF SINGLE MOLECULE FORCE SPECTROSCOPY TO INVESTIGATE BINDING OF INTEGRIN ALPHA(2)BETA(1) AND COLLAGEN
A. M. C. Simpson* (UK), S. J. Attwood, D. Bihan, S. W. Hamaia, M. E. Welland, R. W. Farndale

PP-MO-059 POSSIBLE ROLE OF GNAS1 IMPRINTING IN A PROTHROMBOTIC PHENOTYPE: NESP55 HYPERMETHYLATION IN ISCHEMIC STROKE AT YOUNG AGE
B. Izzi* (BE), R. Bouillon, K. Devriendt, C. van Geet, K. Freson

PP-MO-060 SOLUBLE AGONISTS AND SHEAR FORCES DIFFERENTIALLY ALTER THE LIQUID ORDER OF PLATELET MEMBRANES: QUANTITATIVE MEASURES AND PLATELET SUBPOPULATION DETECTION
B. Labarthe* (CA), A. Maguy, P. Theroux, A. Bonnefoy

PP-MO-061 ATORVASTATIN TREATMENT INCREASES THE LIQUID ORDER OF PLATELET MEMBRANES
B. Labarthe* (CA), A. Maguy, R. Gallo, P. Theroux, A. Bonnefoy

PP-MO-062 REAL-TIME MEASUREMENT OF NON-LETHAL PLATELET THROMBOEMBOLIC RESPONSES IN THE ANAESTHASIZED MICE
C. Tymvios* (UK), C. Moore, M. Emerson

PP-MO-063 OPTIMIZATION OF INTRACELLULAR NITRIC OXIDE ASSESSMENT IN MONOCYTES BY FLOW CYTOMETRY
N. C. C. Schachnik, V. Peruhype-Magalhães, F. Lucas-Junior, G. M. M. Paula, V. M. Freitas, O. A. Martins-Filho, L. M. S. Dusse* (BR)

PP-MO-064 TYPE OF AGONIST DETERMINES THE ROLE OF PLATELETS IN FIBRINOLYSIS. ASSEMBLY OF LRP-1, UPA, UPAR AND PAI-1 COMPLEX IN STIMULATED PLATELETS
O. Panes* (CL), D. Flores, V. Matus, J. Pereira, D. Mezzano

PP-MO-065 MITOCHONDRIAL CONTROL OF PLATELET APOPTOSIS: ROLE OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE
V. Leytin* (CA), A. Mutlu, D. J. Allen, A. V. Gyulkhandanyan, S. Mykhaylov, J. Freedman

PP-MO-066 PLATELET TRANSFUSION INDEPENDENCE ACHIEVED WITH USE OF A THROMBOPOIETIN RECEPTOR (TPO-R) AGONIST IN REFRACTORY SEVERE APLASTIC ANEMIA (SAA)
E. M. Bloch, A. Giermasz* (US), J. Knoche, P. F. Fogarty

PP-MO-067 THE D1424N AND R1933X MUTATIONS OF MYH9 RESULT IN AN ALTERED PROPLATELET FORMATION BY HUMAN MEGAKARYOCYTES
A. Pecci, A. Malara, S. Badalucco, V. Bozzi, C. L. Balduini, A. Balduini* (IT)

PP-MO-068 LACK OF ASPIRIN RESISTANCE IN PREGNANT WOMEN
A. Duncan* (US), A. Winkler, A. Ingle

PP-MO-069 A STUDY ON THE PATHOPHYSIOLOGY OF PREECLAMPSIA – THE PLATELET DYSFUNCTION. A SERIES OF 3 CASES
M. Onisai, R. Vladareanu, A. Vladareanu* (RO), H. Bumbea, S. Radesi, M. Ciorascu, A. Nicolescu, I. Voican

PP-MO-070 TISSUE FACTOR EXPRESSION ON RECIPIENT PLATELETS AND PBMCS IS THE KEY FACTOR IN COAGULATION DYSFUNCTION IN PIG-TO-PRIMATE LIVER TRANSPLANTATION
C. Lin, B. Ekser, B. Gridelli, C. Long, G. Echeverri, H. Hara, M. Ezzelarab, D. Ayares, A. Dorling* (US), D. K. C. Cooper

PP-MO-071 DOES HEMODIALYSIS CAUSE BLOOD PLATELETS APOPTOSIS?
A. Sobol, M. Kaminska, M. Stasiak, J. Szymanski, B. Walkowiak* (PL)

PP-MO-072 SELECTIVE SEROTONIN REUPTAKE INHIBITORS INFLUENCE AGONIST-INDUCED PLATELET AGGREGATION. PRELIMINARY RESULTS FROM COMORBIDITY OF DEPRESSION AND CARDIOVASCULAR DISEASE STUDY
E. Litinas* (US), J. Fareed, O. Iqbal

PP-MO-073 IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN WITH THERAPY MODALITIES
G. Aydogan* (TR), M. Celik, D. Tugcu, Z. Salcioglu, F. Akici, A. Kiyak, A. Akcay, N. Canpolat, H. Sen

PP-MO-074 STUDIES FROM A PATIENT WITH A GRAY PLATELET SYNDROME: EVIDENCE FOR AN ALPHA GRANULE LOCALIZATION OF OSTEOPROTEGERIN (OPG) IN PLATELETS AND MEGAKARYOCYTES. EVALUATION OF MYELOFIBROSIS
M. E. Chollet* (FR), J. P. Brouland, C. Bal Dit Sollier, M. Lebret, F. Bauduer, L. Drouet, S. Bellucci

PP-MO-075 MOLECULAR GENETIC BASIS OF INHERITED THROMBOCYTOPENIA
A. O. Al-Marwani* (UK), D. Pearson, B. Wagner, A. C. Ong, M. Makris, M. E. Daly

PP-MO-076 IDENTIFICATION OF A NOVEL HOMOZYGOUS P2Y12 MUTATION IN A PATIENT WITH A MILD PLATELET-BASED BLEEDING DISORDER
B. B. Dawood* (UK), M. Daly, M. Makris, A. Mumford, S. Watson, J. Wilde

PP-MO-077 FIRST CASE OF CONSTITUTIONAL GVI DEFECT IN A PATIENT HETEROZYGOUS FOR TWO GPVI MUTATIONS
B. Dumont* (FR), D. Lasne, C. Rothschild, M. Bouabdelli, V. Ollivier, N. Ajzenberg, B. Grandchamp, M. Jandrot-Perrus

PP-MO-078 PLATELET MYOSIN LIGHT CHAIN (MYL9) DEFICIENCY IN RUNX1 HAPLODEFICIENCY: MYL9 IS A DIRECT TRANSCRIPTIONAL TARGET OF RUNX1
G. S. Jalagadugula* (US), G. Kaur, G. Mao, D. Dhanasekaran, A. K. Rao

PP-MO-079 ALPHA IIB CARRIES A NEW POLYMORPHISM, IN A+, INVOLVED IN NEONATAL THROMBOCYTOPENIA
V. Jallu, M. Dusseaux, D. Granier, C. Kaplan, G. Bertrand* (FR)

PP-MO-080 PRESENCE OF PLATELET-ASSOCIATED ANTI-GPVI AUTOANTIBODIES AND RESTORATION OF GPVI EXPRESSION IN PATIENTS WITH GPVI DEFICIENCY
M. Akiyama, H. Kashiwagi* (JP), K. Todo, M. Moroi, M. C. Berndt, H. Kojima, Y. Kanakura, Y. Tomiyama

PP-MO-081 GATA-1,G208S MACROTHROMBOCYTES LACK TALIN
J. G. White* (US), S. M. Burris, B. R. Crowe

PP-MO-082 VISUALIZING THE VON WILLEBRAND FACTOR/GLYCOPROTEIN IB-IX AXIS IN PLATELET-TYPE VON WILLEBRAND DISEASE
J. A. Guerrero* (US), S. Russell, T. K. Gartner, B. Storrie, J. Ware

PP-MO-083 A CASE OF SEVERE THROMBOCYTOPENIA ASSOCIATED WITH PENTAMIDINEDEPENDENT ANTIBODY SPECIFIC FOR GLYCPROTEIN IIB
K. S. Heidinger* (DE), A. Giptner, R. Fischer, S. Santoso, G. Bein, U. Sachs

PP-MO-084 A POTENTIAL HOT SPOT FOR UNEQUAL HOMOLOGOUS RECOMBINATION WITHIN EXON 24 OF THE MYH9 GENE
K. Miyazaki* (JP), S. Kunishima, W. Fujii, M. Higashihara

PP-MO-085 DOMINANT INHERITANCE OF A NOVEL INTEGRIN BETA3 MUTATION ASSOCIATED WITH HEREDITARY MACROTHROMBOCYTOPENIA AND PLATELET DYSFUNCTION
P. Gresele, E. Falcinelli, L. Bury* (IT), S. Giannini, P. D’Adamo, A. D’Eustacchio, T. Corazzi, A. Mezzasoma, F. di Bari, G. Guglielmini, L. Cecchetti, P. Noris, C. Balduini, A. Savoia

PP-MO-086 DOSE-DEPENDENT EFFECTS OF ASPIRIN ON PLATELET FUNCTION
M. Sobieraj-Teague* (CA), J. J. I. Weitz, J. J. S. Ginsberg, D. D. Sloane, S. S. Anand, J. J. W. Eikelboom

PP-MO-087 DEPLETION OF NEUTRALIZING ANTI-ADAMTS13 ANTIBODY FROM ACQUIRED TTP PATIENT PLASMA BY ADAMTS13-SPECIFIC AFFINITY ADSORPTION
B. Plaimauer* (AT), S. Skalicky, M. Schmidt, M. Hasslacher, F. Scheiflinger

PP-MO-088 IN VITRO AND IN VIVO ACTIVITY OF TRUNCATED MURINE ADAMTS13 MUTANTS
B. de Maeyer* (BE), S. F. de Meyer, H. B. Feys, H. Deckmyn, K. Vanhoorelbeke

PP-MO-089 STABILISATION OF THE VWF A2 DOMAIN BY INTRODUCTION OF A DISULPHIDE BOND PREVENTS BINDING TO AND CLEAVAGE BY ADAMTS13
B. M. Luken* (UK), L. Y. N. Winn, J. Emsley, D. A. Lane, J. T. B. Crawley

PP-MO-090 VON WILLEBRAND FACTOR IS A MAJOR DETERMINANT OF ADAMTS-13 DECREASE DURING MOUSE SEPSIS INDUCED BY CECUM LIGATION AND PUNCTURE
C. Dunois-Larde* (FR), N. Lerolle, I. Badirou, D. G. Motto, G. Hill, P. Bruneval, J. L. Diehl, C. V. Denis, D. Baruch

PP-MO-091 GLOBULAR VWF INTERACTION WITH C-TERMINAL DOMAINS OF ADAMTS13 SUGGESTS A TWO SITE INTERACTION MECHANISM LEADING TO PROTEOLYSIS
S. Zanardelli, C. K. W. Chion, P. J. Lenting, E. Groot, D. A. Lane* (UK)

PP-MO-092 INTRAPLATELET LOCALIZATION OF ADAMTS13
I. Garagiola, R. Lombardi, A. Artoni, R. de Cristofaro, M. Cattaneo, F. Peyvandi* (IT)

PP-MO-093 IMAGING ANALYSIS OF PLATELET THROMBUS FORMATION IN ADAMTS13-MUTANT MICE
F. Banno* (JP), A. K. Chauhan, K. Kokame, J. Yang, S. Miyata, D. D. Wagner, T. Miyata

PP-MO-094 THE ADAMTS13 S119F MUTATION DECREASES ENZYME ACTIVITY BY ALTERING SUBSITE ORIENTATION
H. B. Feys* (BE), I. Pareyn, R. Vancraenenbroeck, H. Deckmyn, M. de Maeyer, C. van Geet, K. Vanhoorelbeke

PP-MO-095 ONGOING TREATMENT WITH CANGRELOR, BUT NOT TICAGRELOR, IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN THE EFFICACY OF CLOPIDOGREL IN AN EXVIVO CANINE MODEL
A. Ravnefjord* (SE), P. Delavaux, J. Tornvall, J. Weilitz, B. M. Emanuelsson, J. J. J. van Giezen

PP-MO-096 THE EFFECTS OF MAJOR IN VIVO METABOLITES OF PRASUGREL ON HUMAN PLATELET AGGREGATION
A. Sugidachi* (JP), Y. Niitsu, T. Ogawa, J. A. Jakubowski, M. Hasegawa, M. Hashimoto, K. Hagihara, A. Kurihara

PP-MO-097 THE EFFECT OF PLATELET AND PLASMA OXLDL AND PLATELET CHOLESTEROL ON THE ASA-MEDIATED BLOOD PLATELET INHIBITION AND PLATELET PROTEIN ACETYLATION IN ATORVASTATIN-TREATED HYPERCHOLESTEROLEMIC PATIENTS
B. Luzak* (PL), M. Boncler, J. Rywaniak, R. Wilk, L. Stanczyk, J. Rysz, C. Watala

PP-MO-098 INHIBITION OF PLATELET AGGREGATION AUGMENTS FIBRIN CLOT FORMATION IN LARGE ARTERIES AND VEINS
B. C. Cooley* (US)

PP-MO-099 CELLULAR BASES FOR THE EFFICACY OF EPOPROSTENOL IN PULMONARY HYPERTENSION
M. Crescente, C. Tamburrelli, M. Barisciano, W. Zamboni, M. B. Donati, G. de Gaetano, C. Cerletti* (IT)

PP-MO-100 SIMULTANEOUS DIRECT FACTOR Xa INHIBITION AND ACTIVATED PLATELET BLOCKAGE ALLOWS SUPERIOR ANTICOAGULATION WITHOUT BLEEDING TIME PROLONGATION
C. E. Hagemeyer* (AU), S. U. Eisenhardt, N. Bassler, P. Stoll, M. Schwarz, Y. C. Chen, I. Ahrens, C. Bode, K. Peter

PP-MO-101 HARNESSING THE ANTIPLATELET EFFECTS OF PROSTAGLANDIN E2 BY EP3 RECEPTOR BLOCKADE
D. Iyu* (UK), S. Heptinstall

PP-MO-102 SUPPRESSION OF PLATELET AGGREGATION CAUSE BY GLUCOSAMINE SUPPLEMENT
D. L. McGlasson* (US), G. A. Fritsma

PP-MO-103 STUDY OF PLATELET ACTIVITY IN ROUTINE AND ACUTE CORONOARY ANGIOGRAPHY
D. L. McGlasson* (US), G. Patino, B. J. Rubal, A. D. Shah

PP-MO-104 PLATELET MRP4 OVEREXPRESSION IS RESPONSIBLE FOR REDUCED CAMPDEPENDENT INHIBITORY ACTION ON PLATELET FUNCTION
E. Trifiro’, A. Borgognone, D. di Pietrantonio, D. Reale, F. M. Pulcinelli* (IT)

PP-MO-105 SALVIANOLIC ACID A INHIBITS PLATELET ACTIVATION AND ARTERIAL THROMBOSIS VIA THE INHIBITION OF AKT PHOSPHORYLATION
H. Hu* (CN), L. Zhu, Z. Huang, Y. Zhao, N. Li

PP-MO-106 P2Y12 ANTAGONISM INHIBITS SERUM THROMBOXANE GENERATION: IMPLICATIONS FOR COMBINATION THERAPY WITH ASPIRIN
K. Bhavaraju* (US), S. Kim, Y. Mao, J. Jin, S. Kunapuli

PP-MO-107 FUNCTIONAL BLOOD COAGULATION ASSAYS BASED ON THE LOCI® TECHNOLOGY
A. Kappel* (DE), G. Christ

PP-MO-108 ALIMENTARY LIPEMIA IS ASSOCIATED WITH INCREASED PLASMA VIIaAT CONCENTRATION AND THROMBIN GENERATION
A. Silveira* (SE), A. Carlo, B. J. Woodhams, A. Hamsten

PP-MO-109 HUMAN ALTERNATIVELY SPLICED TISSUE FACTOR IS NOT SECRETED AND DOES NOT TRIGGER COAGULATION
A. N. Böing* (NL), C. M. Hau, A. Sturk, R. Nieuwland

PP-MO-110 INR IN LIVER DISEASE: AN ISI DERIVED FROM LIVER DISEASE PATIENTS IMPROVES AGREEMENT BETWEEN INRS WITH DIFFERENT REAGENTS
A. M. Sermon* (UK), J. M. Smith, R. Maclean, S. Kitchen

PP-MO-111 DISTURBED BLOOD FLOW INDUCES EROSIVE INJURY OF TISSUE FACTOR-RICH INTIMA AND PROMOTES THROMBUS FORMATION
T. Sumi, A. Yamashita* (JP), S. Matsuda, K. Nishihira, E. Furukoji, H. Sugimura, T. Imamura, K. Kitamura, S. Goto, Y. Asada

PP-MO-112 HOW TO OVERCOME THE INNER FILTER EFFECT IN FLUORESCENT SUBSTRATE ACTIVITY ASSAYS?
A. Carlo* (FR), C. Vauthier, E. Lebra, T. Fürle, M. Clabon, D. Drilhole, S. Kerdélo, G. Quentin, M. Gonidec, E. Arnaud, B. J. Woodhams

PP-MO-113 NMR STUDIES OF TISSUE FACTOR: SAMPLE PREPARATION AND PARTIAL CHEMICAL SHIFT ASSIGNMENTS
J. M. Boettcher, B. D. Lahood, J. H. Morrissey, C. M. Rienstra* (US)

PP-MO-114 HYPERCOAGULABILITY IS INDEPENDENTLY ASSOCIATED WITH KYNURENINE PATHWAY ACTIVATION IN DIALYZED URAEMIC PATIENTS
D. Pawlak* (PL), M. Mysliwiec, K. Pawlak

PP-MO-115 PRACTICE IN POINT OF CARE INR TESTING-REVIEW OF QUESTIONNAIRES FROM 2001, 2004 AND 2007OF UK NEQAS PARTICIPANTS
D. P. Kitchen* (UK), S. Munroe, S. Kitchen, I. Jennings, T. Woods, I. Walker

PP-MO-116 ESTABLISHMENT OF AN EXTERNAL QUALITY ASSESSMENT PROGRAMME FOR USERS OF ACTIVATED CLOTTING TIME
D. P. Kitchen* (UK), S. Munroe, S. Kitchen, I. Jennings, T. Woods, I. Walker

PP-MO-117 EPITOPE LOCALISATION AND FUNCTIONAL IMPACT OF A MONOCLONAL ANTIBODY RECOGNISING V158D/E296V/M298Q-FACTOR VIIa
E. Persson* (DK)

PP-MO-118 SIGNIFICANCE OF COMPLETE GAMMA-CARBOXYLATION FOR DEVELOPMENT OF A LONG-ACTING GLYCOPEGYLATED COAGULATION FACTOR IX VARIANT
J. R. Bjelke* (DK), P. K. Holm, M. B. Hermit, A. A. Pedersen, J. M. Petersen, B. Kjær, T. N. Krogh, M. Nielsen, K. Vinther, H. Ostergaard

PP-MO-119 PREPARATION OF RECOMBINANT BOVINE TISSUE FACTOR EXPRESSED AS AN INTEGRAL MEMBRANE PROTEIN IN SILKWORM USING A BACULOVIRUS EXPRESSION SYSTEM, AND ITS APPLICATION IN AN OWREN-TYPE (II-VII-X, BOVINE COMBINED) REAGENT
M. Okuda* (JP), T. Taniguchi, K. Kishi, Y. Hamaguchi, H. Nagaya, S. Murayama, A. Usami

PP-MO-120 ANTICOAGULATION OF A PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY AND FACTOR VII DEFICIENCY
S. J. Davidson* (UK), N. Turner, L. Tillyer

PP-MO-121 CLEARANCE OF ACTIVATED RECOMBINANT HUMAN COAGULATION FACTOR VII (RFVIIa) IN RAT AND MOUSE LIVER
T. Seested Johansen* (DK), H. M. Nielsen, E. I. Christensen, R. S. Appa

PP-MO-122 REABSORPTION OF RECOMBINANT ACTIVATED VII (RFVIIa) IN RENAL PROXIMAL TUBULES OF THE KIDNEY IN RODENT MODELS
T. Seested Johansen* (DK), E. I. Christensen, C. Jacobsen, R. S. Appa

PP-MO-123 INHIBITION OF FACTOR XI REDUCES THROMBUS FORMATION IN RABBIT JUGULAR VEIN UNDER CONDITIONS OF ENDOTHELIAL DENUDATION AND/OR BLOOD STASIS
A. Yamashita* (JP), M. Takahashi, S. Moriguchi-Goto, C. Sugita, S. Matsuda, Y. Sato, T. Kitazawa, K. Hattori, Y. Asada

PP-MO-124 THROMBELASTOGRAPHIC DETECTION OF FACTOR XII-LIKE ACTIVITY IN CITRATED WHOLE BLOOD SAMPLES, BUT NOT IN PLASMA OF THE CHICKEN WHITE LEGHORN
B. C. Prezoto* (BR), C. S. S. S. Silva, M. M. Rocha, G. Motta, T. R. F. Rocha

PP-MO-125 CONTINUOUS INFUSION IN THE MANAGEMENT OF SEVERE BLEEDING EPISODES IN HAEMOPHILIA A CHILDREN
B. Pautard Muchemble, B. Pautard* (FR), V. Li Thiao Te, T. Tinot, J. Notheaux Micheli, B. Roussel

PP-MO-126 GLYCOPROTEIN IB-ALPHA MODULATES FACTOR IXa-MEDIATED FACTOR Xa-GENERATION ON THE ACTIVATED PLATELET SURFACE
C. Weeterings* (NL), P. G. de Groot, T. Lisman

PP-MO-127 FACTOR VIII CONTRIBUTES TO PLATELET-FIBRIN THROMBUS FORMATION VIA THROMBIN GENERATION UNDER LOW SHEAR CONDITIONS
C. Sugita* (JP), A. Yamashita, S. Moriguchi-Goto, E. Furukoji, M. Takahashi, A. Harada, T. Soeda, T. Kitazawa, K. Hattori, S. Tamura, Y. Asada

PP-MO-128 FOUR NOVEL KLKB1 MUTATIONS IN SEVEN FAMILIES WITH SEVERE PREKALLIKREIN DEFICIENCY
C. Geisen* (DE), J. Farac, D. Delev, M. Compes, B. Just, J. G. Kadar, A. Siegemund, B. Zieger, E. Seifried, J. Oldenburg

PP-MO-129 IMPACT OF ANALYTICAL VARIABLES ON INTRINSIC FACTOR ASSAYS RESULTS: NORTH AMERICAN SPECIAL COAGULATION LABORATORY ASSOCIATION (NASCOLA) PROFICIENCY TESTING FROM 2003-2007
D. D. Castellone* (US), E. E. I. B. Peerschke

PP-MO-130 HEREDITARY ANGIOEDEMA DUE TO MISSENSE MUTATIONS IN THE COAGULATION FACTOR XII GENE - THREE NOVEL CASES
E. Aygören Pürsün* (DE), G. Dewald, E. Rusicke, I. Martinez-Saguer, W. Kreuz

PP-MO-131 PHOSPHATIDYLSERINE-INDEPENDENT PLATELET BINDING SITES FOR FACTOR VIII
G. E. Gilbert* (US), J. Shi, C. Bai, J. Lu, J. T. Rasmussen, C. W. Heegaard

PP-MO-132 THE RATIO BETWEEN THE ACTIVITIES OF COAGULATION FACTOR XII AND C1 ESTERASE INHIBITOR MAY BE A RISK PREDICTOR FOR ANGIOEDEMA
G. Moessmer* (DE)

PP-MO-133 PLASMA PREDILUTION WITH ADDITION OF DEPLETED PLASMA IN A PT-REAGENT IMPROVES THE AGREEMENT BETWEEN DIFFERENT PROTHROMBIN TIME METHODS
A. Osman* (SE), T. L. Lindahl

PP-MO-134 SEVERE BIOCHEMICAL AND FUNCTIONAL EFFECTS IN ANTITHROMBIN CAUSED BY ACROLEIN
A. Ordóñez* (ES), S. Pedersen, J. A. Guerrero, A. Miñano, R. Teruel, C. Martínez, L. Velázquez, S. R. Kristensen, V. Vicente, J. Corral, I. Martínez-Martínez

PP-MO-135 THE INFLUENCE OF CYP2C9 GENETIC POLYMORPHISMS ON ORAL ANTICOAGULANT DOSE REQUIREMENTS IN THE LEBANESE POPULATION
N. Zgheib, M. Esmerian, Z. Mitri, G. Zaatari, S. Alam, H. Skouri, R. Mahfouz, A. Taher* (LB)

PP-MO-136 ASSAY DEPENDENT VARIATIONS IN THE USP POTENCY STANDARDIZED UNFRACTIONATED HEPARINS
A. Gray* (US), D. Hoppensteadt, L. Myers, O. Iqbal, C. Adiguzel, J. Fareed

PP-MO-137 COMPARISON OF A NOVEL ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UPLC-MS/MS) METHOD WITH THE ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) AND PROTHROMBIN TIME (PT)
A. M. Winkler* (US), M. L. Synder, A. Duncan, R. J. Molinaro

PP-MO-138 DOWN-REGULATION OF PROTEIN S EXPRESSION BY 17BETA-ESTRADIOL IN HEPG2 CELLS
A. Suzuki* (JP), N. Sanda, K. Makita, Y. Miyawaki, Y. Fujimori, T. Yamada, A. Takagi, T. Murate, H. Saito, T. Kojima

PP-MO-139 DIFFERENTIAL THROMBIN GENERATION INHIBITION BY BRANDED AND GENERIC LOW MOLECULAR WEIGHT HEPARINS (LMWHS) AS STUDIED BY USING FLUORESCENCE SUBSTRATE BASED KINETIC METHOD
C. Adiguzel* (US), E. Litinas, J. Cunanan, D. Hoppensteadt, J. M. Walenga, J. Fareed

PP-MO-140 GENERIC VERSIONS OF ARGATROBAN CAN BE DIFFERENTIATED FROM BRANDED ARGATROBAN IN THE THROMBIN GENERATION ASSAYS (TGA)
C. Adiguzel* (US), E. Litinas, O. Iqbal, J. Cunanan, W. Jeske, D. Hoppensteadt, J. Walenga, J. Fareed

PP-MO-141 TESTSTRIP-BASED GENOTYPING TO ASSIST IN THE PREDICTION OF ANTICOAGULANT DOSE REQUIREMENT
H. Puehringer, G. Klose, B. Schreyer, W. Krugluger, R. M. Loreth, C. Oberkanins* (AT)

PP-MO-142 VITAMIN K DEFICIENCY IN INJECTING DRUG USERS
D. Dawson* (UK)

PP-MO-143 ACTIVATION OF PREKALLIKREIN BY CONTAMINATED HEPARINS, ISOLATED CONTAMINANT AND RELATED HYPERSULFATED CHONDROITIN SULFATE PREPARATIONS: PHARMACOLOGIC IMPLICATIONS
D. Hoppensteadt* (US), O. Iqbal, H. Messmore, C. Adiguzel, V. Bansal, J. Fareed

PP-MO-144 FIRST TYPE II ANTITHROMBIN DEFICIENCY CAUSED BY A LARGE INSERTION. STRUCTURAL AND FUNCTIONAL RELEVANCE
I. Martínez-Martínez* (ES), T. Sevivas, N. Gómez, A. Ordóñez, A. Miñano, A. I. Antón, J. Padilla, M. E. de La Morena, R. González-Conejero, V. Vicente, J. Corral

PP-MO-145 ENCAPSULATION OF HEPARIN IN POLYMERIC NANOPATICLES
C. Pazzini, P. D. Marcato, N. Durán, S. A. L. Montalvão, N. F. Höehr, J. M. Annichino-Bizzacchi* (BR)

PP-MO-146 THE INVESTIGATION OF PROTEIN-PROTEIN INTERACTIONS IN HEMOSTATIC SYSTEM USING ENZYME ELECTROPHORESIS METHOD
A. I. Zhukova* (MN), I. Krasnobrysha, O. M. Savchuk, G. L. Volkov

PP-MO-147 INDUSTRIAL PURIFYING METHOD OF THROMBIN-LIKE ENZYME
B. B. Jonj* (MN), T. P. Buhan

PP-MO-148 PATIENTS WITH ENHANCED CLOT SOLUBILITY IN ACID CONDITIONS REQUIRE DIFFERENTIATION BETWEEN RAISED PLASMA LEVELS OF THE ASPARTIC PROTEASE PEPSINOGEN I AND INHIBITORY ANTIBODIES TO FACTOR XIII
E. M. Duncan* (AU), B. Dale, J. V. Lloyd

PP-MO-149 HAEMOSTASIS AFFECTING PROTEASES FROM VIPERA LEBETINA SNAKE VENOM
E. Siigur* Estonia, K. Tonismagi, M. Samel, H. Vija, K. Trummal, A. Aaspollu, J. Subbi, J. Siigur

PP-MO-150 RECOMBINANT HUMAN COAGULATION FACTOR IX (RFIX): INFLUENCE OF SERINE PHOSPHORYLATION AND TYROSINE SULFATION ON PHARMACOKINETIC PROPERTIES IN FIX-KNOCK-OUT MICE
E. Böhm* (AT), M. Dockal, M. Hasslacher, C. Konetschny, A. Mitterer, E. M. Muchitsch, M. Reiter, F. Scheiflinger

PP-MO-151 VARIATION AND CONSERVATION IN THE B-DOMAIN OF FACTOR V
H. L. Vos* (NL), A. van Wijngaarden

PP-MO-152 CROSS-REACTIVITY OF RABBIT ANTI-BOVINE THROMBIN IGGS WITH HUMAN ATHROMBIN AND A RECOMBINANT VERSION OF HUMAN THROMBIN (RECOTHROM TM)
H. Zhu* (US), D. Hoppensteadt, R. Wahi, J. Fareed

PP-MO-153 RELATIVE PURITY OF IMPROVED TOPICAL BOVINE THROMBIN PREPARATIONS
H. Zhu* (US), D. Hoppensteadt, R. Wahi, J. Fareed

PP-MO-154 COMPARATIVE IMMUNOGENIC POTENTIALS OF CRUDE AND PURIFIED BOVINE THROMBIN PREPARATIONS
H. Zhu* (US), D. Hoppensteadt, O. Iqbal, R. Wahi, J. Fareed

PP-MO-155 ROLE OF THE INTERACTION BETWEEN THE FACTOR VIII A1 DOMAIN CA2+ BINDING SITE AND C2 DOMAIN ON ACTIVITY AND STABILITY
H. Wakabayashi* (US), A. E. Griffiths, P. J. Fay

PP-MO-156 DEFINITION OF THE THROMBIN-BINDING SITE ON THE HUMAN FACTOR VIII C2 DOMAIN
J. C. Lin* (US), J. Schuman, S. M. Nakaya, K. P. Pratt

PP-MO-157 THROMBIN CLEAVAGE AT ARG1689 INFLUENCES HEAVY CHAIN CLEAVAGE DURING ACTIVATION OF FACTOR VIII
J. L. Newell* (US), P. J. Fay

PP-MO-158 AN ENGINEERED COAGULATION FACTOR IX WITH AUGMENTED ACTIVITY: USING MOUSE MODELS TO CHARACTERIZE THE CLOTTING FUNCTION IN VIVO AND FURTHER EVALUATE THE THROMBOSIS RISK
C. Y. Kao, C. N. Lin, I. S. Yu, S. R. Lin, M. H. Tao, H. L. Wu, G. Y. Shi, C. C. Fang, S. W. Lin* (TW)

PP-MO-159 SEQUENCE IN THE FIRST INTRON OF FXIII A SUBUNIT GENE IS INVOLVED IN REGULATING THE EXPRESSION OF FXIII A SUBUNIT GENE
W. Cai* (CN), L. L. H. Huang, X. X. L. Liu, G. G. L. Li

PP-MO-160 INHIBITORS IN CHILDREN DURING SECONDARY PROPHYLAXIS FOR HEMOPHILIA IN A DEVELOPING COUNTRY
A. Linares* Colombia, M. Aristizabal, I. Sarmiento, S. Castaño, M. Cortes

PP-MO-161 THE COMPLETE ISOLATED N-TERMINAL EXTENSION OF HEPARIN COFACTOR II IS REQUIRED FOR MAXIMAL THROMBIN BINDING
A. J. Boyle* (CA), V. Bhakta, W. P. Sheffield

PP-MO-162 MONITORING OF RIVAROXABAN: SUITABILITY OF A WELL-ESTABLISHED CHROMOGENIC ANTI-FACTOR Xa ASSAY
A. Karst* (DE), B. Bakowski-Enzian, E. Perzborn

PP-MO-163 LOW INHIBITOR INCIDENCE IN PREVIOUSLY UNTREATED HAEMOPHILIA A PATIENTS TREATED WITH OCTANATE
A. Klukowska* (PL), P. Laguna, M. Jansen

PP-MO-164 CAN PROTEIN C AND PROTEIN S DEFICIENT PATIENTS BE IDENTIFIED DURING ORAL ANTICOAGULANT TREATMENT?
A. B. Münster* (DK), J. J. Sidelmann, J. Gram, J. Jespersen

PP-MO-165 HEPARAN SULFATE FROM HUMAN FOLLICULAR FLUID CONTAINS ABUNDANT 3-OSULFATED CHAINS WITH HIGH ANTICOAGULANT ACTIVITY
A. I. de Agostini* (CH), A. Fischer, N. W. Shworak, L. Zhang, R. J. Linhardt

PP-MO-166 SUCCESSFUL MANAGEMENT OF MAJOR SURGERY WITH IVIG IN A PATIENT WITH A PROGRESSIVE ACQUIRED VON WILLEBRAND FACTOR INHIBITOR ON THE BACKGROUND OF HEREDITARY TYPE 1 VON WILLEBRAND’S DISEASE
B. Madan* (UK), G. W. Moore, P. Earnshaw, D. A. Gurney

PP-MO-167 RISK OF BLEEDING WITH DABIGATRAN ETEXILATE IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IS NOT INCREASED BY CONCOMITANT USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS OR ACETYLSALICYLIC ACID
B. I. Eriksson* (SE), A. A. Kurth, R. J. Friedman, J. M. Schnee, A. Clemens, H. Noack, J. A. Caprini

PP-MO-168 RESULTS OF THE ECAT WORKSHOP ON THE DETECTION OF COAGULATION INHIBITORS
B. Verbruggen* (NL), P. Meijer

PP-MO-169 NON-PARALLELISM IN THE ONE-STAGE FACTOR ASSAYS IS A PHENOMENON OF LUPUS ANTICOAGULANTS AND NOT OF PARTICULAR FACTOR INHIBITORS
J. Ruinemans-Koerts, B. Verbruggen* (NL), I. Peterse-Stienissen

PP-MO-170 COMPARISON OF DIFFERENT MONITORING METHODS FOR DIRECT THROMBIN INHIBITOR, LEPIRUDIN
B. Salmela* Finland, L. Joutsi-Korhonen, R. Lassila

PP-MO-171 ACQUIRED HAEMOPHILIA A IN CHINA:REVIEW AND META-ANALYSIS FOCUSED ON CLINICAL CHARACTERS AND MANAGEMENT
C. Zheng* (CN), J. Wu, K. Ding, W. Zhu, X. Cai

PP-MO-172 NANIPROIN, A NOVEL PROTHROMBINASE COMPLEX INHIBITOR FROM NAJA NIGRICOLLIS VENOM
C. Y. Koh* (SG), B. H. See, R. Kini

PP-MO-173 HEREDITARY ANTITHROMBIN DEFICIENCY CAUSED BY HETEROZYGOUS CAMBRIDGE II MUTATION IN COMBINATION WITH A LARGE GENE DELETION
C. Orlando* (BE), K. Jochmans, W. Lissens, I. Liebaers, M. de Waele

PP-MO-174 IDENTIFICATION OF LARGE GENE DELETIONS IN THE ANTITHROMBIN GENE BY MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION
C. Orlando* (BE), K. Jochmans, W. Lissens, I. Liebaers, M. de Waele

PP-MO-175 ANTICOAGULANT ACTIVITIES OF EP42675, SYNTHETIC DIRECT THROMBIN AND INDIRECT FACTOR Xa INHIBITOR
C. Bal Dit Sollier* (FR), E. Neuhart, C. Krezel, M. Petitou, L. Drouet

PP-MO-176 ENHANCEMENT OF CLOT LYSIS BY ANTICOAGULANTS: DABIGATRAN IS MORE EQUAL THAN HEPARIN
C. T. Ammollo* (IT), F. Semeraro, C. Carrieri, R. Galasso, N. Semeraro, M. Colucci

PP-MO-177 UNFRACTIONATED HEPARIN PROMOTES ELIMINATION OF HUMAN RECOMBINANT MAMMALIAN TFPI IN A RAT MODEL
C. Øie* (NO), E. Brodin, I. Hilden, R. Appa, B. Smedsrød, J. B. Hansen

PP-MO-178 SOLUBLE EPCR INHIBITS THE PROCOAGULANT ACTIVITIES OF FACTOR VIIa: AN EXPLANATION FOR ITS ROLE IN THROMBOSIS
C. Puy* (ES), J. Lopez-Sagaseta, J. Hermida, R. Montes

PP-MO-179 DIRECT LOW-MOLECULAR FXa- AND/OR FIIa-INHIBITORS HAVE NO RISK FOR HIT TYPE II: EFFECTS OF PF4 ON THROMBIN GENERATION INHIBITED BY RIVAROXABAN, DABIGATRAN AND NEW DUAL FIIA/FXa-INHIBITORS
D. Pillitteri* (DE), T. Scholz, D. Westrup, M. Krause, C. M. Kirchmaier

PP-MO-180 ACQUIRED FACTOR XIII DEFICIENCY IN A CHILD
C. Y. Hu, R. Saksena, R. Ricafort, D. Manwani* (US)

PP-MO-181 MECHANISMS OF INHIBITION OF FACTOR XIa AND TRYPSIN BY PROTEASE NEXIN 2 AND BASIC PANCREATIC TRYPSIN INHIBITOR
D. Navaneetham* (US), D. Sinha, P. N. Walsh

PP-MO-182 NEW THROMBIN INHIBITORS: STRATEGY OF MOLECULAR DESIGN AND EXPERIMENTAL TESTING
E. I. Sinauridze* (RU), A. N. Romanov, I. V. Gribkova, O. A. Kondakova, A. S. Gorbatenko, Y.
V. Kuznetsov, A. A. Bogolyubov, M. Y. Manakov, V. B. Sulimov, F. I. Ataullakhanov

PP-MO-183 PROTHROMBIN COMPLEX CONCENTRATE REVERSES THE EFFECTS OF HIGH-DOSE RIVAROXABAN IN RATS
E. Perzborn* (DE), H. Tinel

PP-MO-184 INHIBITION OF THROMBIN GENERATION IN HUMAN PLASMA BY RIVAROXABAN, AN ORAL, DIRECT FACTOR Xa INHIBITOR
E. Perzborn* (DE), M. Harwardt

PP-MO-185 ASSESSMENT OF FACTOR Xa CHROMOGENIC ASSAYS FOR MEASURING THE PHARMACODYNAMICS OF RIVAROXABAN – AN ORAL, DIRECT FACTOR Xa INHIBITOR
E. Perzborn* (DE), M. Hardwardt, M. M. Samama

PP-MO-186 LOW PLASMA LEVELS OF FULL-LENGTH TISSUE FACTOR PATHWAY INHIBITOR IN TYPE I PROTEIN S-DEFICIENT INDIVIDUALS
E. Castoldi* (NL), P. Simioni, D. Tormene, J. Rosing, T. M. Hackeng

PP-MO-187 DESIGN OF A RECOMBINANT ANTITHROMBIN VARIANT AS A POTENT ANTIDOTE FOR FONDAPARINUX AND OTHER HEPARIN DERIVATIVES
E. P. Bianchini* (FR), V. Picard, J. Fazavana, D. Borgel

PP-MO-188 COMPONENTS OF VARIABILITY OF THE EFFECT OF ACTIVATED PARTIAL THROMBOPLASTIN TIME VS. ANTI-FACTOR Xa ON UNFRACTIONATED HEPARIN DOSE ADJUSTMENTS
F. Guerrero* (FR), A. Faucher, V. Diemert, S. Voisin, P. Sié, A. Bura Rivière

PP-MO-189 PHOSPHOINOSITIDES INTERACT WITH PROTEIN C INHIBITOR (PCI)
F. Wahlmüller* (AT), M. Furtmüller, B. Sokolikova, B. R. Binder, M. Geiger

PP-MO-190 NEBULIZED RECOMBINANT HUMAN TFPI ATTENUATES PULMONARY COAGULOPATHY DURING STREPTOCOCCUS PNEUMONIAE PNEUMONIA
F. E. van den Boogaard* (NL), J. H. Hofstra, C. van ‘t Veer, J. J. T. H. Roelofs, M. M. Levi, T. van der Poll, M. J. Schultz

PP-MO-191 NEBULIZED RECOMBINANT HUMAN TFPI ATTENUATES COAGULATION AND LIMITS BACTERIAL OUTGROWTH IN A RAT MODEL OF GRAM–NEGATIVE PNEUMONIA
F. E. van den Boogaard* (NL), J. J. H. Hofstra, C. van ‘t Veer, J. J. T. H. Roelofs, M. M. Levi, T. van der Poll, M. J. Schultz

PP-MO-192 IDENTIFICATION OF MUTATIONS IN THE PROTEIN C GENE ASSOCIATED WITH THE RISK OF VENOUS TROMBOSIS
P. Medina, S. Navarro, A. Vayá, F. Ferrando, M. T. Contreras, A. Estellés, F. Espana* (ES)

PP-MO-193 INFLUENCE OF THE HAPLOTYPE 1 OF THE ENDOTHELIAL PROTEIN C RECEPTOR GENE ON THE CIRCULATING ACTIVATED PROTEIN C LEVELS DURING ORAL ANTICOAGULANT THERAPY
S. Navarro, P. Medina, F. Ferrando, A. Vayá, M. T. Contreras, A. Estelles, F. Espana* (ES)

PP-MO-194 ANTI-FIBROGENIC EFFECTS OF THE DIRECT THROMBIN INHIBITOR DABIGATRAN IN LUNG FIBROBLASTS
G. S. Bogatkevich* (US), R. M. Silver

PP-MO-195 A C.-39C>T NOVEL POINT MUTATION IN THE 5’-UT REGION OF PROS-1 GENE ASSOCIATED WITH PS DEFICIENCY
S. Labrouche, C. Vergnes, G. Freyburger* (FR)

PP-MO-196 MLPA SCREENING OF THE PROS1 GENE: FINDING OF A NEW LARGE DELETION IN THREE PATIENTS WITH PROTEIN S DEFICIENCY
S. Labrouche, C. Vergnes, C. Conri, J. Constans, G. F. Freyburger* (FR)

PP-MO-197 COMPARISON OF RECOMBINANT AND PLASMA-DERIVED ANTITHROMBIN BIODISTRIBUTION IN VIVO
L. R. Berry, B. Thong, H. M. Atkinson* (CA), A. K. C. Chan

PP-MO-198 EFFECT OF FOOD ON DISPOSITION OF DU-176B: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS IN CAUCASIAN AND JAPANESE HEALTHY VOLUNTEERS
J. Mendell* (US), M. Tachibana, M. Shi, S. Kunitada

PP-MO-199 RESISTANCE TO HEPARINS IN A SUBJECT WITH ANTITHROMBIN BUDAPEST III
P. C. Cooper, K. P. Hickey* (UK), R. Jones, R. Krishna, S. Kitchen, R. M. Maclean, A. Goodeve, K. K. Hampton, J. van Veen, M. Makris

PP-MO-200 A CHROMOGENIC SCREENING ASSAY IDENTIFIES THROMBOBOTIC RISK FACTORS IN PRE-SURGERY PATIENTS
M. Johnston* (CA), M. Rupwate, J. McGrath, M. Smirnov, O. Safa, M. Triscott

PP-MO-201 SYNERGISTIC EFFECT OF TAK-442, A DIRECT FACTOR Xa INHIBITOR, AND ANTIPLATELET AGENTS ON WHOLE BLOOD COAGULATION AND ARTERIAL THROMBOSIS IN RATS
N. Konishi, K. Hiroe, E. Shinozawa, Y. Imaeda, K. Kubo, M. Kawamura* (US)

PP-MO-202 EFFECT OF A LOW MOLECULAR WEIGHT HEPARIN ON VASCULAR CELL TISSUE FACTOR EXPRESSION
E. Napoleone, A. Cutrone, G. Colavecchia, F. Calanni, G. de Gaetano, M. B. Donati, R. Lorenzet* (IT)

PP-MO-203 THE PREVALENCE AND GENETIC BACKGROUND OF FACTOR VIII INHIBITORS IN CHINESE HEMOPHILIA A PATIENTS
X. Wang* (CN), Q. Ding, R. Yang, Y. Zhao, J. Wu, J. Sun, X. Zhang, H. Wang

PP-MO-204 SEVERE BLEEDING, CRYOFIBRINOGENAEMIA (CF) AND RHEUMATOID ARTHRITIS (RA)
A. N. Blanco* (AR), S. Grosso, L. A. Bastos, J. Speroni, A. Sanchez Luceros, F. Alberto, M. Aixalá, S. Meschengieser, M. Lazzari

PP-MO-205 FACTOR XIII IN CEREBROSPINAL FLUID
A. Csapó* (HU), É. Katona, G. Szucs, G. Haramura, L. Muszbek

PP-MO-206 FIBRINOGEN KRAKOW: A HETEROZYGOUS CASE OF A NOVEL HYPODYSFIBRINOGENEMIA (GASN325ILE) AFFECTING FIBRIN ARCHITECTURE AND FUNCTION
A. Undas* (PL), J. Zdziarska, T. Iwaniec, E. Stepien, A. Skotnicki, P. de Moerloose, M. Neerman-Arbez

PP-MO-207 EFFECT OF CIGARETTE SMOKING ON PLASMA FIBRIN CLOT PROPERTIES
A. Undas* (PL), E. Stepien, R. Topor-Madry, T. Miszalski-Jamka, W. Tracz, M. Pasowicz

PP-MO-208 FIBRINOGEN POLYMORPHISMS AND THE RISK OF ACUTE ONSET ISCHEMIC STROKE IN YOUNG ASIAN INDIANS
A. Biswas* (IN), R. Ranjan, A. Meena, M. S. Akhter, B. K. Yadav, M. Behari, R. Saxena

PP-MO-209 FIBRINOGEN AND CHOLESTEROL PLASMATIC LEVELS ARE INDEPENDENT CARDIOVASCULAR RISK FACTORS? LIFESTYLE MODIFICATION CAN MODULATE THESE LEVELS?
C. A. Villaverde* (ES), J. Rodriguez, C. Fernandez, D. Bleda, E. Peña

PP-MO-210 RETROSPECTIVE EVALUATION OF DYSFIBRINOGENAEMIC PATIENTS IN A SINGLE CENTRE: CLINICAL FEATURES AND LABORATORY FINDINGS
C. Santoro* (IT), A. Leporace, F. Biondo, R. Asselta, S. Duga, M. Menegatti, M. Platè, M. Mazzucconi

PP-MO-211 ADSORPTION-INDUCED FIBRINOGEN SELF-ASSEMBLY: EVIDENCE OF ESSENTIAL ALPHA-C DOMAIN AND «A» KNOB ROLES
D. K. Galanakis* (US), J. Koo, B. Kudryk, M. Rafailovich

PP-MO-212 THE ROLE OF FRAGMENT BBETA121-138 IN FIBRIN PROTOFIBRIL LATERAL ASSOCIATION
E. V. Lugovskoy* (UA), P. G. Gritsenko, I. N. Kolesnikova, N. E. Lugovskaya, S. V. Komisarenko

PP-MO-213 FIBRINOGEN YECHEON : CONGENITAL DYSFIBRINOGENEMIA WITH GAMMA METHIONINE-310 TO THREONINE SUBSTITUTION
E. Park* (KR), G. Park, R. Park, H. Kim, S. Lee, S. Park, Y. Cha

PP-MO-214 INDUCTION OF CATALYTIC ACTIVITY OF PLASMINOGEN BY MONOCLONAL ANTIBODY A5E10 IN THE PRESENCE OF PLASMINOGEN ACTIVATORS
A. Maleki* (IR), M. Akrami, M. Mirshahi, A. Pourfathollah

PP-MO-215 EXPRESSION OF PROTEOLYTIC AND ANGIOGENIC FACTORS IN ENDOMETRIAL CELL CULTURE FROM ENDOMETRIOSIS. INFLUENCE OF PERITONEAL FLUID
R. Cosin, J. Gilabert-Estelles, L. A. Ramon, M. Gomez-Lechon, F. España, J. Gilabert, M. Chirivella, A. Estelles* (ES)

PP-MO-216 ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH IDIOPATHIC VENOUS THROMBOEMBOLISM
A. Undas* (PL), K. Zawilska, M. Ciesla-Dul, A. Lehmann-Kopydlowska, A. Skubiszak, K. Ciepluch, W. Tracz

PP-MO-217 A HYPOFIBRINOLYTIC STATE IS ASSOCIATED WITH RETINAL VEIN OCCLUSION
A. Cellai* (IT), S. Fedi, D. Lami, B. Giambene, A. Sodi, U. Menchini, R. Marcucci, R. Abbate, G. Gensini, D. Prisco

PP-MO-218 RATIO BETWEEN TIME OF XIIa-DEPENDENT FYBRINOLYSIS (FS) AND ANTITHROMBIN III (AT) ACTIVITY AS A MARKER OF SEVERITY OF SEPSIS
A. V. Krechetova* (RU), G. M. Galstyan, E. B. Orel, S. A. Vasiliev, M. G. Alexanyan, V. M. Gorodetsky

PP-MO-219 CHARACTERIZATION AND APPLICATION OF MONOCLONAL ANTIBODIES TOWARD MOUSE PAI-1
B. van de Craen* (BE), H. R. Lijnen, I. Scroyen, P. J. Declerck, A. Gils

PP-MO-220 DIAGNOSIS OF HYPERFIBRINOLYSIS : WHICH TEST(S) SHOULD BE USED ?
S. Eeckhoudt, D. Latinne, C. Lambert* (BE), C. Hermans

PP-MO-221 THE EFFECTS OF HYPERGLYCAEMIA ON THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR
C. J. N. Verkleij* (NL), M. Nieuwdorp, V. E. A. Gerdes, M. Mörgelin, J. C. M. Meijers, P. F. Marx

PP-MO-222 PLASMA LEVELS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 AND VITRONECTIN IN CHILDREN WITH SOLID TUMORS
D. Tugcu, O. Devecioglu, A. Unuvar* (TR), O. B. Ekmekci, H. Ekmekci, A. Karatas, Z. Karakas, G. Ozturk, S. Anak, L. Agaoglu

PP-MO-223 EVALUATION OF THE INNOVANCE D-DIMER ANALYTICAL PERFORMANCE
D. Coen Herak* (HR), M. Milos, R. Zadro

PP-MO-224 IMPAIRED FIBRINOLYSIS AS A RISK FACTOR FOR BUDD-CHIARI SYNDROME
J. Hoekstra, F. W. Leebeek, A. H. Guimaraes, S. D. Murad, J. J. Malfliet, A. Plessier, P. Langlet, E. Elias, J. Trebicka, M. Primignani, J. Garcia-Pagán, D. C. Valla, H. L. Janssen, D. C. Rijken* (NL)

PP-MO-225 IDENTIFICATION OF MONOCLONAL ANTIBODIES THAT IMPAIR THE ACTIVATION OF BOTH MOUSE AND HUMAN TAFI THROUGH DIFFERENT MECHANISMS
E. Vercauteren* (BE), M. Peeters, P. J. Declerck, A. Gils

PP-MO-226 DERIVATION OF A CLINICAL PREDICTION RULE THAT INCLUDES D-DIMER TO IDENTIFY HIGH-RISK PATIENTS WITH PULMONARY EMBOLISM: FINDINGS FROM THE RIETE REGISTRY
E. Grau* (ES), J. Tenias, J. Ferrer, M. Guil, R. Sanchez, A. Riera, J. Sahuquillo, B. Vasco

PP-MO-227 D-DIMER AND SHORT-TERM CLINICAL OUTCOME OF PULMONARY EMBOLISM: ROLE OF PULMONARY ARTERY CLOT LOAD
E. Grau* (ES), M. Santos, R. Garcia, J. Ferrer, S. Isarria, J. Sanchez, S. Selfa, R. Molina, J. Tenias

PP-MO-228 FACTOR XIII LEVELS IN PATIENTS WITH DIFFERENT STAGES OF ALCOHOLIC LIVER CIRRHOSIS
É. Katona* (HU), B. Garai, I. Tornai, É. Csák, L. Muszbek

PP-MO-229 PROCARBOXYPEPTIDASE U (TAFI) CONSUMPTION IN ACUTE ISCHEMIC STROKE CORRELATES WITH STROKE SEVERITY, EVOLUTION AND OUTCOME E. Heylen* (BE), R. Brouns, J. Willemse, P. de Deyn, D. Hendriks

PP-MO-230 THROMBOLYTIC TREATMENT ALTERS THE PROCARBOXYPEPTIDASE U (TAFI) CONSUMPTION PROFILE IN ISCHEMIC STROKE PATIENTS
E. Heylen* (BE), R. Brouns, J. Willemse, P. de Deyn, D. Hendriks

PP-MO-231 O-LINKED GLYCOSYLATION OF VWF IS AN IMPORTANT MODULATOR OF ADAMTS13 PROTEOLYSIS AND BINDING TO GPIB
A. A. Nowak* (UK), G. Angus, M. A. Laffan, T. A. J. McKinnon

PP-MO-232 THE ROLE OF CAMP IN THE GENE EXPRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 AND TISSUE FACTOR IN ADIPOCYTE
A. Hayashi* (JP), N. Ono, A. Tomita, H. Takeya

PP-MO-233 STUDY OF D-DIMER LEVELS USING TWO DIFFERENT IMMUNOTURBIDOMETRIC ASSAYS AT DIFFERENT STAGES OF PREGNANCY
A. A. Khalafallah* (AU), M. Morse, A. Dennis, J. Bates, G. Bates, L. Smith, G. Mishra, N. Blesingk, I. Robertson, D. Seaton, T. Brain

PP-MO-234 ANGIOTENSIN-(1-9) ENHANCES VENOUS THROMBOSIS DEVELOPMENT IN RAT BY INHIBITING FIBRINOLYTIC ACTIVITY
A. Mogielnicki* (PL), K. Kramkowski, D. Pawlak, J. M. Hermanowicz, W. Buczko

PP-MO-235 REGULATORY FUNCTIONS OF POSITIVE FEEDBACKS OF FACTORS V AND VII ACTIVATION IN BLOOD CLOTTING INITIATION
A. N. Balandina* (RU), M. A. Panteleev, A. M. Shibeko, I. I. Shmirev, F. I. Ataullakhanov

PP-MO-236 ESTROGEN RECEPTORS MEDIATE CHANGES IN MOUSE PLASMA COAGULATION FACTOR LEVELS AND HEPATIC TRANSCRIPT LEVELS INDUCED BY ORAL ETHINYLESTRADIOL
A. C. A. Cleuren* (NL), I. K. van der Linden, P. H. Reitsma, B. J. M. van Vlijmen

PP-MO-237 PLATELET FACTOR 4 (CXCL4) SHIELDS PLASMA FACTOR V TO THROMBIN AND RETARDS ACTIVATION
A. A. Amelot, M. Tagzirt, J. Libraire, B. F. Le Bonniec* (FR)

PP-MO-238 NATURAL COURSE OF ENDOGENOUS PLASMA ACTIVATED PROTEIN C LEVELS AND EFFECT OF DROTRECOGIN ALFA (ACTIVATED) ON MARKERS OF COAGULATION ACTIVATION AND FIBRINOLYSIS IN ACUTE PULMONARY EMBOLISM TREATED WITH THERAPEUTIC DOSE ENOXAPARIN: A RANDOMIZED, DOUBLE-BLIND STUDY
C. H. Dempfle* (DE), A. Link, E. Elmas, N. Suvajac, V. Liebe, J. Janes, M. Borggrefe

PP-MO-239 INHIBITION OF GAMMA A AND GAMMA’ FIBRINOGEN SYNTHESIS BY INTERFERONGAMMA OCCURS THROUGH A STAT1 MEDIATED MECHANISM
C. M. Rein* (US), D. H. Farrell

PP-MO-240 COMPARISON OF CLOTTING FACTOR STABILITY IN LYOPHILIZED PLASMA AND S/DPLASMA STORED FOR 6 DAYS AT 4°C
C. von Heymann* (DE), M. K. Keller, A. Pruss, M. Sander, H. Schoenefeld, U. Kalus, C. Rosenthal, C. Spies

PP-MO-241 THE EFFECT OF THE ADDITION OF FXIII TO FRESH FROZEN PLASMA ON COAGULATION AND CLOT FIRMNESS IN A MODEL OF DILUTIONAL COAGULOPATHY
C. von Heymann* (DE), C. Rosenthal, M. K. Keller, M. Schuster, C. Spies

PP-MO-242 PLATELET PROTEIN S ANTIGEN LEVELS IN CONGENITAL PROTEIN S DEFICIENCY
C. Radu* (IT), L. Spiezia, D. Tormene, C. Bulato, S. Gavasso, M. Perlati, M. Fadin, P. Simioni

PP-MO-243 DECREASED LEVELS OF PLATELET PROTEIN S IN PATIENTS UNDER TREATMENT WITH WARFARIN
C. Bulato* (IT), C. Radu, S. Gavasso, G. Tognin, L. Spiezia, P. Zerbinati, P. Simioni

PP-MO-244 THE NOVEL ANTICOAGULANT SOLULIN PROMOTES REPERFUSION AND REDUCES INFARCT VOLUME IN A THROMBOTIC MODEL OF STROKE
E. J. Su* (US), M. Geyer, M. Wahl, M. Warnock, K. Mann, H. Brohmann, K. Petersen, D. A. Lawrence

PP-MO-245 THE NOVEL DIRECT THROMBIN INHIBITOR DABIGATRAN ACCELERATES PLASMA FIBRINOLYSIS THROUGH TAFI-DEPENDENT AND -INDEPENDENT MECHANISMS
F. Semeraro* (IT), C. T. Ammollo, N. Semeraro, M. Colucci

PP-MO-246 QUENCHING OF THROMBIN GENERATION BY ANTITHROMBIN III (AT-III) AS MEASURED BY THROMBINOSCOPE IN NORMAL AND ALTERED CLOTTING PROCESSES
F. Carmassi* (IT), F. de Negri, F. Mori, I. Nardini

PP-MO-247 BLEEDING CONCERNS DRIVE PRACTICES OF ORTHOPEDIC SURGEONS IN PREVENTION OF VENOUS THROMBOEMBOLISM IN PRIMARY HIP AND KNEE ARTHROPLASTY
F. A. Anderson* (US), D. Ayers, C. Colwell, F. Cushner, R. Friedman, M. Huo, G. Fitzgerald, L. Kwong

PP-MO-248 PRACTICES IN PREVENTION OF VENOUS THROMBOEMBOLISM IN PRIMARY HIP AND KNEE ARTHROPLASTY VARY WITH SURGEON OPERATIVE VOLUME: FINDINGS FROM A SURVEY OF US ORTHOPEDIC SURGEONS
F. A. Anderson* (US), J. Lieberman, V. D. Pellegrini, A. C. Spyropoulos, A. G. Turpie, G. Westrich, P. Franklin, D. Warwick

PP-MO-249 A QUANTITATIVE MODEL FOR THE HUMORAL COAGULATION NETWORK
G. K. Isbister* (AU), T. Wajima, S. B. Duffull

PP-MO-250 THE ROLE OF BARRELS 1 AND 2 IN ENZYMATIC ACTIVITY OF FACTOR XIIIa
E. L. Smith, P. J. Adamson, R. A. S. Ariëns, M. C. Maurer, P. J. Grant, H. Philippou* (UK)

PP-MO-251 CALIBRATED THROMBIN GENERATION FROM A SINGLE MEASURING WELL
H. C. Hemker* (NL), R. Al Dieri, P. W. Hemker

PP-MO-252 INTRACELLULAR CYCLIC AMP UP-REGULATES EXPRESSION OF THROMBINACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) IN CULTURED HUMAN HEPATOMA HEPG2 CELLS
H. Ishii* (JP), Y. Masuda, K. Takada, K. Sugimoto

PP-MO-253 ACTIVATION OF FIBRINOLYSIS AND BLEEDING HISTORY IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS
H. Seidel* (DE), H. J. Hertfelder, K. Alfter, U. W. Kolck, I. von Kügelgen, J. Homann, J. Oldenburg, G. J. Molderings

PP-MO-254 THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR GENETIC POLYMORPHISMS AS MARKERS OF THE TYPE OF ACUTE CORONARY SYNDROME
D. Tassies, M. Roque, J. Monteagudo, T. Martorell, A. Sionis, D. Arzamendi, M. Heras, J. C. Reverter* (ES)

PP-MO-255 PROCOAGULANT EFFECT OF PLASMIN DEPENDENT ON FACTOR V AND FACTOR VIII DURING THE BLOOD COAGULATION PROCESS
K. Ogiwara* (JP), K. Nogami, K. Nishiya, M. Takeyama, M. Shima

PP-MO-256 OXYTOCIN INFLUENCE ON HAEMOSTASIS SYSTEM AND BEHAVIORAL REACTION IN WHITE RAT BY NORMAL AND STRESSOGENIC CONDITION
M. Golubeva* (RU), M. Grigorjeva, O. Voscresenskaya

PP-MO-257 EFFECT OF, UMBILICAL CORD, BLOOD CELLS IN THE “EXPRESSION” OF PLATELET GLYCOPROTEIN RECEPTORS
M. P. Makris* (GR), M. Moshou, D. Vasileiadou, G. Koliakos, P. E. Makris

PP-MO-258 CAN PROTEINS INDUCED BY VITAMIN K ABSENCE - PIVKA II - DETECT SUBCLINICAL VITAMIN K DEFICIT IN MAJOR SURGERY?
U. Schott* (SE), P. Anveden, K. Strandberg, P. Flisberg, M. Engström, A. Hillarp

PP-MO-259 LONG-TERM FOLLOW-UP IN PATIENTS WITH POSITIVE ANTIPHOSPOLIPID ANTIBODIES – SINGLE CENTRE EXPERIENCE
A. Bulikova* (CZ), D. Harustiakova, J. Zavrelova, L. Dusek, M. Penka

PP-MO-260 THE PARAMETERS OF IMMUNE INFLAMMATION AND HAEMOSTASIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH ANTIPHOSPHOLIPID SYNDROME (APS) AND WITHOUT APS
A. V. Arshinov* (RU), V. I. Emanuylov, N. V. Zubova

PP-MO-261 ENDOGENOUS THROMBIN POTENTIAL (ETP) ANALYSIS OF LUPUS ANTICOAGULANT PLASMA WITH THE BMS (DADE BEHRING SIEMENS) SYSTEM
A. D’Angelo* (IT), P. Della Valle, E. Pattarini, L. Crippa, A. Fattorini

PP-MO-262 THE LIPOPROTEIN DISTRIBUTION OF BETA-2-GLYCOPROTEIN I (APOLIPOPROTEIN H)
C. Agar* (NL), P. G. de Groot, J. H. M. Levels, J. A. Marquart, J. C. M. Meijers

PP-MO-263 THE LUPUS RATIO TESTS IMPROVE THE DIAGNOSIS OF LUPUS ANTICOAGULANTS
C. Nougier* (FR), F. Sobas, G. Baud, C. Negrier

PP-MO-264 LABORATORY DIAGNOSIS OF LUPUS ANTICOAGULANT: HOW MANY TESTS?
C. Nougier* (FR), Y. Chevalier, F. Sobas, C. Negrier

PP-MO-265 A LYOPHILIZED LUPUS ANTICOAGULANT NEGATIVE CONTROL PREPARED ACCORDING TO ISTH LA RECOMMENDATIONS
D. Sanchez* (US), C. Cueto, J. Vasquez, R. Bottenus, M. Triscott

PP-MO-266 CEREBRAL MR AND SPECT ABNORMALITIES IN PATIENTS WITH DEEP VEIN THROMBOSIS OR STROKE IN ANTI-PHOSPHOLIPID SYNDROME
D. Barcellona, A. Mameli, S. Cornacchini, L. Casciu, M. Piga, F. Marongiu* (IT)

PP-MO-267 IS LUPUS ANTICOAGULANT TESTING USEFUL IF APTT IS NORMAL?
A. Mameli, D. Barcellona, L. Fenu, M. Vannini, F. Marongiu* (IT)

PP-MO-268 ANALYSIS OF LETHAL OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND ANTIPHOSPHOLIPID SYNDROME (APS) BASED ON LONG-TERM FOLLOW-UP
T. M. Reshetnyak, I. B. Shtivelband* (RU), E. N. Alexandrova, E. S. Mach, L. V. Kondratyeva, E. V. Ostryakova, A. A. Novikov, E. L. Nasonov

PP-MO-269 TUMOUR NECROSIS FACTOR ALPHA AND SOLUBLE INTERLEUKIN 2 RECEPTOR (SIL-2R) LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
J. Swadzba* (PL), T. Iwaniec, J. Musial

PP-MO-270 FUNCTIONAL VARIANTS OF PLATELET GLYCOPROTEINS IA/IIA AND IIB/IIIA AND VALINE/LEUCINE247 POLYMORPHISM OF BETA 2- GLYCOPROTEIN I AND A RISK OF ARTERIAL THROMBOSIS IN PATIENTS WITH ANTIPHOSHOLIPID SYNDROME
J. Swadzba* (PL), A. Matyja-Bednarczyk, M. Sanak, S. Dziedzina, T. Iwaniec, A. Bulikova, J. Musial

PP-MO-271 ARTERIAL THROMBOSIS IN PATIENTS WITH ANTIPHOSHOLIPID SYNDROME
J. Swadzba* (PL), A. Matyja-Bednarczyk, T. Iwaniec, A. Bulikova, J. Musial

PP-MO-272 EVALUATION OF A NEW ENZYME IMMUNOASSAY FOR DETECT AND QUANTIFICATION OF HUMAN ANTICARDIOLIPIN ANTIBODIES
J. Needham* (UK), S. Knight, S. Rangarajan

PP-MO-273 PROSPECTIVE STUDY OF THE CLINICAL AND SEROLOGICAL CHARACTERISTICS AND LONG-TERM EVOLUTION OF THE ANTIPHOSPHOLIPID SYNDROME AT THE AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER
L. Bazzi* (LB), A. Taher, R. Mahfouz, I. Uthman

PP-MO-274 B2 GLYCOPROTEIN I (B2GPI) CONTAINING IGM IMMUNE-COMPLEXES (B2GPI-IGM IC) IN PATIENTS WITH IGM ANTICARDIOLIPIN ANTIBODIES (ACL IGM)
M. F. Alberto* (AR), A. Sanchez Luceros, S. Meschengieser, M. A. Lazzari

PP-MO-275 THE IMPORTANCE OF APPROPRIATED CRITERIA FOR LUPUS ANTICOAGULANT (LA) DIAGNOSIS
M. E. Martinuzzo* (AR), G. Cerrato, M. Iglesias Varela, Y. Adamczuk, R. Forastiero

PP-MO-276 LUPUS ANTICOAGULANT IN NIGERIAN WOMEN WITH POOR OBSTETRICS HISTORY
O. A. Awodu* (NG), A. O. Ejele, W. A. Shokunbi

PP-MO-277 THROMBOPHILIC GENE MUTATION IN RECURRENT MISCARRIAGE
Z. Mostafa* (EG), N. Abulata, S. Sahlab, A. Shams Eldin

PP-MO-278 HEMOSTASIS AND HEMATOLOGICAL THROMBOTIC RISK FACTORS IN YOUNG NIGERIAN SEMI VEGETARIANS
A. A. Adeyemi* (NG), O. A. Omolade, Y. O. Makinde, O. I. Ajayi, O. A. Awodu, A. A. Famodu

PP-MO-279 JAK2 MUTATIONS OTHER THAN JAK2 V617F MAY BE ABSENT IN PATIENTS WITH UNUSUAL SITE THROMBOSIS
A. H. Tabares* (AR), A. L. Basquiera, N. Soria, M. Salguero, R. Ryser, J. J. García

PP-MO-280 DIFFERENCES IN VENOUS THROMBOEMBOLISM MANAGEMENT IN THREE EUROPEAN COUNTRIES: RESULTS FRO THE RIETE REGISTRY
J. P. Cambou, N. Hassairi, A. Bura* (FR)

PP-MO-281 VENOUS THROMBOEMBOLIC DISEASE IN MEN AND WOMEN: DATA FROM THE RIETE REGISTRY
A. Bura* (FR), J. Ben Cheik, J. P. Cambou

PP-MO-282 VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE
A. Iorio* (IT), C. Kearon, E. Filippucci, M. Marcucci, V. Pengo, G. Agnelli, G. Palareti

PP-MO-283 FAVORABLE OUTCOMES WITH ONCE DAILY FONDAPARINUX 2.5MG VS. ENOXAPARIN 40MG FOR THROMBOPROPHYLAXIS AFTER ABDOMINAL OR MAJOR ORTHOPEDIC SURGERY
A. F. Shorr* (US), R. V. Horblyuk, O. E. Lunacsek, L. A. Menditto, M. A. Franklin

PP-MO-284 ROLE OF LIPID LOWERING THERAPY (LLT) ON VENOUS THROMBOEMBOLISM (VTE) RISK: A POPULATION-BASED CASE-CONTROL STUDY
A. A. Ashrani* (US), J. A. Heit, M. K. Barsoum, C. L. Leibson, T. M. Petterson, K. R. Bailey, L. J. Melton

PP-MO-285 THE RISK OF VENOUS THROMBOEMBOLIC EVENTS AFTER SPLENECTOMY. PROSPECTIVE OBSERVATIONAL COHORT STUDY IN 412 CONSECUTIVE PATIENTS
A. Ghirarduzzi* (IT), F. Landini, S. Corradini, M. Iotti, I. Barbieri, F. Biolchini

PP-MO-286 INFLUENCE OF EXOGENOUS RISK FACTORS TO THE FACTOR V LEIDEN PARADOX IN MEN AND WOMEN – RESULTS FROM A RETROSPECTIVE THROMBOPHILIC FAMILY COHORT
A. B. U. Mäkelburg* (NL), W. M. Lijfering, N. J. G. M. Veeger, S. Middeldorp, K. Hamulyak, M. H. Prins, H. R. Büller, J. van der Meer

PP-MO-287 PROTEIN C DEFICIENCY AND RISK OF THROMBOSIS
A. Cafolla* (IT), E. Baldacci, N. Angelosanto, P. Pignoloni, F. Biondo, M. Mazzucconi

PP-MO-288 ANTIPHOSPHOLIPID ANTIBODIES IN WOMEN WITH A HISTORY OF PREGNANCYRELATED VENOUS THROMBOSIS (VT) - A POPULATION-BASED CASE-CONTROL STUDY
A. Bergrem* (NO), E. M. Jacobsen, F. E. Skjeldestad, A. F. Jacobsen, P. M. Sandset

PP-MO-289 THROMBOPHILIA, HYPERCOAGULABILITY, AND ENVIRONMENT, AND THE RISK OF VENOUS THROMBO-EMBOLISM (THE-VTE STUDY)
A. van Hylckama Vlieg* (NL), F. R. Rosendaal, C. A. Baglin, R. Luddington, T. P. Baglin

PP-MO-290 D-DIMER AND AGE AS RISK FACTORS FOR RECURRENCE AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM IN THE EXTENDED FOLLOW-UP OF THE PROLONG STUDY
B. Cosmi* (IT), C. Legnani, V. Pengo, A. Ghirarduzzi, S. Testa, A. Alatri, P. Domenico, D. Poli, A. Tripodi, G. Palareti

PP-MO-291 D-DIMER AND SEX AS RISK FACTORS FOR RECURRENCE AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM IN THE EXTENDED FOLLOW-UP OF THE PROLONG STUDY
B. Cosmi* (IT), C. Legnani, V. Pengo, A. Tosetto, A. Ghirarduzzi, A. Alatri, D. Prisco, D. Poli, A. Tripodi, G. Palareti

PP-MO-292 PRESENCE OF A PRO-THROMBOTIC STATE IN PATIENTS WITH CUSHING’S SYNDROME: A SYSTEMATIC REVIEW ON THE INFLUENCE OF ENDOGENOUS HYPERCORTISOLISM ON HEMOSTASIS AND VENOUS THROMBOSIS
B. van Zaane* (NL), E. Nur, A. Squizzato, O. M. Dekkers, M. T. H. B. Twickler, E. Fliers, V. E. A. Gerdes, H. R. Buller, D. P. M. Brandjes

PP-MO-293 THE EFFECT OF LEVOTHYROXINE ON COAGULATION AND FIBRINOLYSIS IN HEALTHY VOLUNTEERS: A SINGLE BLINDED CROSSOVER RANDOMISED CONTROLLED TRIAL
B. van Zaane* (NL), A. Squizzato, J. Debeij, O. M. Dekkers, J. C. M. Meijers, H. R. Buller, V. E. A. Gerdes, S. C. Cannegieter, D. P. M. Brandjes

PP-MO-294 RISK FACTORS FOR PULMONARY EMBOLISM
B. Milli* (IT), A. Rocci, M. Riccò, M. Lombardi, R. Quintavalla

PP-MO-295 CYTOMEGALOVIRUS INFECTION IS ASSOCIATED WITH VENOUS THROMBOEMBOLISM - A CASE-CONTROL STUDY
S. Schimanski, B. Linnemann, B. Luxembourg, J. Rochon, E. Seifried, E. Lindhoff-Last, C. M. Schambeck* (DE)

PP-MO-296 PERFORMANCE CHARACTERISTICS OF AN ELISA FOR QUANTITATION OF ADAMTS13 AUTOANTIBODIES IN HUMAN PLASMA
C. J. Hoecke* (US), H. J. L. Fryer, E. Guinto, R. S. Greenfield

PP-MO-297 EVALUATION OF THROMBOSIS GENETIC PREDISPOSITION IN SÃO MIGUEL ISLAND HEALTHY POPULATION
C. C. Branco* (PT), T. Pereirinha, P. R. Pacheco, R. Cabral, L. Mota-Vieira

PP-MO-298 VENOUS THROMBOSIS IS ASSOCIATED WITH HYPERGLYCEMIA AT DIAGNOSIS: A CASE-CONTROL STUDY
D. M. Cohn* (NL), J. Hermanides, J. H. Devries, P. W. Kamphuisen, R. Huijgen, J. C. M. Meijers, J. B. L. Hoekstra, H. R. Büller

PP-MO-299 SIMPLIFICATION OF THE PULMONARY EMBOLISM SEVERITY INDEX FOR PROGNOSTICATING PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM
D. Jiménez* (ES), D. Aujesky, L. Moores, D. Marti, J. Lobo, F. Uresandi, R. Otero, M. Monreal, R. Yusen

PP-MO-300 PROTHROMBIN LEVELS ARE INCREASED IN TYPE II DIABETICS
D. L. Sauls* (US), R. McFarland, A. Brogden, M. Hoffman

PP-MO-301 METABOLIC SYNDROME IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN KOREAN POPULATION
D. Oh* (KR), M. Jang, W. Choi, S. Bang, T. Lee, Y. Kim, W. Ageno

PP-MO-302 IS THERE FAMILIAL CLUSTERING OF ELEVATED FACTOR VIII?
E. Vagdatli* (GR), K. Mitsopoulou, F. Tsikopoulou, E. Pantziarela, O. Serafimidou, E. Protonotariou, E. Kazantzidou

PP-MO-303 HYPERHOMOCYSTEINEMIA AND RISK OF VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PULMONARY EMBOLISM
E. Grifoni* (IT), G. Ciuti, D. Poli, E. Antonucci, R. Marcucci, C. Arcangeli, M. Miniati, G. Gensini, R. Abbate, D. Prisco

PP-MO-304 OBESITY AS A POSSIBLE RISK FACTOR FOR INCOMPLETE RESTORATION OF PULMONARY PERFUSION AFTER PULMONARY EMBOLISM (PE)
E. Grifoni* (IT), D. Poli, E. Antonucci, G. Ciuti, R. Marcucci, C. Arcangeli, G. Gensini, R. Abbate, D. Prisco, M. Miniati

PP-MO-305 TYPE AND LOCATION OF VENOUS THROMBOEMBOLISM IN FV LEIDEN CARRIERS; EXPERIENCE FROM A SINGLE CENTER
E. Papadakis* (GR), A. Spyrou, S. Efraimidou, K. Loukidhs, H. Kartsios, M. Topalidou, I. Korantzis

PP-MO-306 HEMORRHAGE IN ACUTE CARE SETTING IS A RISK FACTOR FOR LATER VENOUS THROMBOEMBOLISM IN REHABILITATION UNIT
E. Tincani* (IT), A. Bernardini, M. A. Crowther, M. Foroni

PP-MO-307 A GENOME WIDE ASSOCIATION STUDY TO IDENTIFY CANDIDATE GENES FOR HIGH FACTOR VIII LEVELS IN VENOUS THROMBOEMBOLISM: DO ABOGLYCOSYLTRANSFERASES PLAY AN IMPORTANT ROLE?
F. Thieme* (DE), A. Fiebig, T. Lu, B. Luxembourg, H. von Eller-Eberstein, B. Flesch, M. Spannagl, E. Lindhoff-Last, S. Schreiber, C. M. Schambeck

PP-MO-308 NATURAL HISTORY OF MESENTERIC VENOUS THROMBOSIS IN PATIENTS TREATED WITH ORAL ANTICOAGULANTS
F. Dentali* (IT), W. Ageno, D. Witt, A. Malato, N. Clark, D. Garcia, K. McCool, S. Siragusa, M. Crowther

PP-MO-309 JAK2V617F MUTATION FOR THE EARLY DIAGNOSIS OF PH- MYELOPROLIFERATIVE NEOPLASMS IN PATIENTS WITH VENOUS THROMBOEMBOLISM. A META-ANALYSIS
F. Dentali* (IT), A. Squizzato, L. Brivio, L. Appio, L. Campiotti, M. Crowther, A. M. Grandi, W. Ageno

PP-MO-310 ELEVATED THROMBIN GENERATION IN RELATIVES OF PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM AND NO DETECTABLE THROMBOPHILIA
F. Couturaud* (FR), J. Duchemin, G. Quere, C. Kearon, J. Ginsberg, C. Leroyer, D. Mottier, J. Abgrall

PP-MO-311 CHRONOLOGY OF THE INCIDENCE OF VENOUS THROMBOEMBOLISM ALONG THE FIRST THREE MONTHS AFTER PROXIMAL FEMUR FRACTURE IN ELDERLY PATIENTS
A. B. C. Machado, M. L. Sobreira, G. J. C. Pereira, J. E. Corrente, F. H. A. Maffei* (BR)

PP-MO-312 THE ITALIAN PULMONARY EMBOLISM REGISTRY “IPER”: PRELIMINARY RESULTS
C. Becattini, F. Casazza* (IT), A. Rubboli, L. Roncon, P. Zonzin, C. D’Agostino, A. Bongarzoni, P. Favretto, G. Agnelli

PP-MO-313 HIGH LEVELS OF VON WILLEBRAND FACTOR ANTIGEN AND FACTOR VIII IN PATIENTS WITH CHRONIC POSTTRAUMATIC STRESS DISORDER
B. Makhoul, O. Rubichek, E. Klein, B. Brenner, G. Sarig* (IL)

PP-MO-314 TISSUE FACTOR ACTIVITY OF BLOOD MONONUCLEAR CELLS, BUT NOT PLASMA ANTIGEN, IS INCREASED AFTER TOTAL KNEE ARTHROPLASTY
G. J. Johnson* (US), L. A. Leis, R. R. Bach

PP-MO-315 VENOUS THROMBOEMBOLISM IN THE ELDERLY: EPIDEMIOLOGICAL DATA OVERVIEW BASED ON THE 2149-PATIENTS PROSPECTIVE OPTIMEV COHORT
G. Pernod* (FR), J. Bosson, M. Sevestre, J. Labarere

PP-MO-316 KIDNEY DISEASE AND RISK OF VENOUS THROMBOSIS
G. Ocak* (NL), C. Y. Vossen, M. Verduijn, K. J. van Stralen, F. W. Dekker, C. J. M. Doggen, F. R. Rosendaal

PP-MO-317 INCIDENCE OF THROMBOPHILIC DISORDERS IN WOMEN OF CHILDBEARING AGE AND A HISTORY OF THROMBOEMBOLISM OR RECURRENT PREGNANT LOSS VS. A HEALTHY CONTROL GROUP
H. Schinzel* (DE), E. Rolfes, L. Walter, A. Viertel, D. Peetz

PP-MO-318 ADEQUACY OF VENOUS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS (IMPART): PRELIMINARY REPORT OF A MULTISITE COMPARISON OF DIFFERENT DECISION SUPPORT SYSTEMS
M. R. Nendaz, P. Chopard, C. Lovis, J. Doerffler, N. Kucher, L. Asmis, D. Spirk, H. Bounameaux* (CH)

PP-MO-319 LOW ADAMTS13 ANTIGEN AND ACTIVITY AND THE PRESENCE OF ADAMTS13 AUTOANTIBODY SUGGEST ADAMTS13 MAY PLAY A ROLE IN VENOUS THROMBOEMBOLISM
H. J. L. Fryer* (US), C. J. Hoecke, J. R. Wu, E. Guinto, R. S. Greenfield

PP-MO-320 REFERENCE RANGES IN THROMBOPHILIA SCREENING
I. Jennings* (UK), D. P. Kitchen, S. Kitchen, T. A. L. Woods, I. D. Walker

PP-MO-321 LIVING NEAR MAJOR TRAFFIC ROADS AND RISK OF DEEP VEIN THROMBOSIS
I. Martinelli* (IT), A. Baccarelli, V. Pegoraro, P. A. Bertazzi, J. Schwartz, P. M. Mannucci

PP-MO-322 FACTOR V LEIDEN MUTATION INCREASES THE RISK FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH MALIGNANCY
I. Pabinger* (AT), D. Dunkler, R. Vormittag, C. Ay, C. Marosi, R. Simanek, C. Zielinski, C. Mannhalter

PP-MO-323 MUTATION SCREENING FOR THE C46T VARIANT IN THE F12 GENE BY MELTING POINT ANALYSIS WITH THE LIGHTCYCLER SYSTEM: ATYPICAL RESULTS, DETECTION OF THE VARIANT G47A
I. Tirado* (ES), I. Coll, E. Martínez-Sánchez, A. Santamaría, E. Martí, J. Fontcuberta

PP-MO-324 RECURRENT THROMBOSIS IN NORTH INDIAN PATIENTS AND THE ROLE OF THROMBOPHILIC RISK FACTORS
J. Ahluwalia* (IN), R. Das, P. Malhotra, N. Varma, S. Varma

PP-MO-325 PERSISTENT HIGH FACTOR VIII ACTIVITY LEADING TO INCREASED THROMBIN GENERATION
J. K. Ryland* (UK), A. S. Lawrie, S. J. Machin, I. J. Mackie

PP-MO-326 VENOUS THROMBOEMBOLISM IN THE EMERGENCY DEPARTMENT: INCIDENCE, DIAGNOSIS AND CLINICAL CHARACTERISTICS OF PATIENTS
K. Hitos* (AU), A. Singh, N. Gunja, J. P. Fletcher

PP-MO-327 INFLUENCE OF PROCARBOXYPEPTIDASE U LEVEL AND THR325ILE POLYMORPHISM ON CLINICAL EXPRESSION OF THROMBOPHILIA IN CARRIERS OF FV LEIDEN OR FII 20210A MUTATION
P. S. Miljic* (RS), E. Heylen, J. L. Willemse, V. Djordjevic, M. Colovic, I. Elezovic, D. F. Hendriks

PP-MO-328 THROMBOTIC RISK FACTORS IN PATIENTS WITH LIVER CIRRHOSIS: CORRELATION WITH MELD SCORING SYSTEM AND PORTAL VEIN THROMBOSIS DEVELOPMENT
R. de Cristofaro* (IT), M. Zocco, E. di Stasio, S. Lancellotti, M. Pompili, G. Rapaccini, R. Landolfi, A. Gasbarrini

PP-MO-329 A COMMON GENETIC VARIANT OF FACTOR XIII A SUBUNIT VAL34LEU PREDISPOSES TO VENOUS THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
M. Sanak, T. Iwaniec* (PL), S. Dziedzina, J. Musial

PP-MO-330 ASSOCIATION BETWEEN FACTOR XII C46T POLYMORPHISM AND THROMBOTIC DISEASES IN TAIWAN AND ITS PARTICULAR ROLE IN MALE PATIENTS
Y. B. Yu* (TW), J. P. Gau, C. C. Chen, J. Y. You, H. C. Hsu, Y. C. Hong, C. Y. Liu, P. M. Chen, T. S. Lee, C. H. Tzeng

PP-MO-331 ASSESSMENT OF PULMONARY HYPERTENSION IN PATIENTS AFFECTED BY PULMONARY EMBOLISM (PE)
A. Barchitta* (IT), L. Ruzza, F. Tosato, A. C. Pessina, V. Pengo

PP-MO-332 CARDIOVASCULAR AND THROMBO-EMBOLIC RISK FACTORS AND ANTECEDENTS IN IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS: THE ACOBRUSK STUDY
A. Stepanian* (FR), I. Mosnier, F. Defay, G. Baron, F. Tankere, C. Bodenez, A. Robier, P. Bertholon, B. Fraysse, B. Meyer, O. Sterkers, D. de Prost

PP-MO-333 ABO BLOOD GROUP POLYMORPHISMS IN BRAZILIAN PATIENTS WITH VASCULAR ARTERIAL DISEASE
A. P. Fernandes* (BR), A. P. Sabino, D. D. Ribeiro, G. G. Lages, M. S. Santos, T. Gadelha, L. S. Dusse, M. Carvalho

PP-MO-334 PLASMINOGEN ACTIVATOR INHIBITOR -1 (PAI-1) 4G5G POLYMORPHISM AND PAI-1 ENZYME ACTIVITY IN YOUNG PATIENTS WITH ISCHEMIC STROKE
M. S. Santos, A. P. Sabino, M. G. Carvalho, D. D. Ribeiro, T. Gadelha, L. S. Dusse, A. P. Fernandes* (BR)

PP-MO-335 EVALUATION OF POLYMORPHISMS IN APOLIPOPROTEIN B GENE AND THE RISK OF ISCHEMIC STROKE IN YOUNG PATIENTS
A. P. Fernandes* (BR), C. G. M. Santos, M. Carvalho, A. P. Sabino, D. D. Ribeiro, T. Gadelha, M. O. Sousa, K. B. Gomes

PP-MO-336 IMPACT OF THROMBOPHILIA IN YOUNG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
A. Guida* (IT), A. Tufano, M. N. D. di Minno, M. di Capua, A. M. de Gregorio, G. Quintavalle, A. Russolillo, A. Coppola, E. Cimino, A. M. Cerbone, G. di Minno

PP-MO-337 THROMBIN GENERATION IS A MARKER OF CLINICAL OUTCOME AFTER ACUTE MYOCARDIAL INFARCTION
A. W. J. H. Dielis* (NL), M. Smid, H. M. H. Spronk, R. van Oerle, M. Winkens, K. Hamulyak, J. Rosing, M. H. Prins, J. Waltenberger, H. ten Cate

PP-MO-338 COAGULATION MARKERS LEVELS MEASURED DURING ACUTE INFECTION MAY PREDICT THE DEVELOPMENT OF LONG TERM CARDIO- AND CEREBRO-VASCULAR EVENTS IN ELDERLY
A. Winder* (IL), T. Bruzgol, I. Lichman, A. Herman, E. Leibovitz, E. Rachmilewitz, D. Gavish

PP-MO-339 RELEVANT RISK OF BLEEDING IN ATRIAL FIBRILLATION PATIENTS ON WARFARIN WAITING FOR ELECTIVE CARDIOVERSION
D. Poli* (IT), E. Antonucci, E. Grifoni, G. Ciuti, R. Marcucci, S. Fedi, G. Gensini, R. Abbate, D. Prisco

PP-MO-340 BLEEDING RISK DURING ORAL ANTICOAGULATION IN ATRIAL FIBRILLATION PATIENTS OLDER THAN 80 YEARS
D. Poli* (IT), E. Antonucci, E. Grifoni, R. Marcucci, L. Mannini, R. Abbate, G. F. Gensini, D. Prisco

PP-MO-341 STROKE RISK IN ATRIAL FIBRILLATION PATIENTS ON WARFARIN: PREDICTIVE ABILITY OF RISK STRATIFICATION SCHEMES FOR PRIMARY AND SECONDARY PREVENTION
D. Poli* (IT), E. Antonucci, E. Grifoni, G. Ciuti, R. Marcucci, L. Mannini, G. F. Gensini, R. Abbate, D. Prisco

PP-MO-342 ELEVATED D-DIMER LEVELS ARE ASSOCIATED WITH CORONARY ARTERY DISEASE AND CARDIOVASCULAR DEATH IN AN ANGIOGRAPHICALLY-STUDIED POPULATION
D. Girelli* (IT), N. Martinelli, A. Castagna, N. Campostrini, P. Guarini, S. Friso, F. Pizzolo, F. Busti, L. Annarumma, R. Corrocher, O. Olivieri

PP-MO-343 ASSOCIATION BETWEEN GENETIC VARIATION AT THE ADAMTS13 LOCUS AND ISCHEMIC STROKE
E. Hanson* (SE), K. Jood, S. Nilsson, C. Blomstrand, C. Jern

PP-MO-344 A PEDIATRIC PATIENT WITH ACUTE STROKE DUE TO CEREBRAL ARTERY THROMBOSIS
E. Turkkan* (TR), F. Pekun, D. Yalcin Atay

PP-MO-345 FIBRIN POLYMERIZATION RATE (FPR) AS A CARDIOVASCULAR RISK FACTOR AND CORONARY RISK PREDICTOR
A. E. Ramirez, E. Cortina* (MX), R. A. Izaguirre

PP-MO-346 ANALYSIS OF THE ASSOCIATION BETWEEN THE POLYMORPHISM PLA1/A2 OF THE PLATELET GLYCOPROTEIN IIB/IIIA GENE AND THE RISK OF ISCHEMIC STROKE IN YOUNG PATIENTS
F. F. Coelho* (BR), A. P. Fernandes, K. B. Gomes, C. G. Miranda, M. G. Carvalho, A. P. Sabino, T. Gadelha

PP-MO-347 EFFECT OF THE DIRECT THROMBIN INHIBITOR, DABIGATRAN, ON ARTERIAL THROMBOSIS WHEN GIVEN IN COMBINATION WITH ASPIRIN (ASA) IN A CYCLIC FLOW MODEL IN ANESTHETISED PIGS
J. van Ryn* (DE), T. Dietze, I. Kuritsch, M. Kink-Eiband, W. Wienen

PP-MO-348 DECREASE FACTOR VIIa/ANTITHROMBIN COMPLEXES IN CHILDREN WITH ISCHEMIC STROKE
L. Spiezia* (IT), V. Rossetto, S. Gavasso, G. Tognin, B. Brandolin, B. Woodhams, P. Simioni

PP-MO-349 INCREASED FACTORS VIII AND VON WILLEBRAND IN TYPE 2 DIABETES WOMEN AND THEIR ASSOCIATION TO MACROVASCULAR DISEASE EXTENT
M. G. Carvalho* (BR), M. O. Sousa, M. A. Borges, P. W. Rosario, G. F. G. Lages, A. Fernandes, A. Soares

PP-MO-350 ASSOCIATION OF HAEMOSTATIC AND INFLAMMATORY MARKERS WITH FUTURE ISCHEMIC CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE - INITIAL LABORATORY RESULTS OF THE PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (PID
M. Bedencic* (SI), A. Blinc, M. Bozic Mijovski, M. Stegnar, M. Kozak, M. Sabovic, P. Poredos,
A. Kravos, B. Barbic-Zagar, M. Pohar-Perme, J. Stare

PP-MO-351 THROMBOPHILIC RISK FACTORS AND PERIPHERAL ARTERIAL DISEASE SEVERITY
M. Sartori* (IT), E. Favaretto, C. Legnani, A. Amato, M. Cini, A. Caniato, M. Filippini, G. Palareti

PP-MO-352 PLASMA LEVELS OF FIBRINOLYTIC PROTEINS AND THE RISK OF MYOCARDIAL INFARCTION IN MEN
M. E. Meltzer* (NL), C. J. M. Doggen, J. C. M. Meijers, P. G. de Groot, F. R. Rosendaal, T. Lisman

PP-MO-353 POLYMORPHISMS OF TUMOR NECROSIS FACTOR-ALPHA AND HYPOXIA INDUCIBLE FACTOR 1ALPHA GENES ARE ASSOCIATED WITH PLASMA HOMOCYSTEINE LEVEL AND SUSCEPTIBILITY TO ISCHEMIC STROKE AND SILENT BRAIN INFARCTION (SBI)
N. Kim* (KR), J. Lee, O. Kim, J. Choi, D. Rim, S. Lee, D. Oh

PP-MO-354 ACTIVATION OF COAGULATION SYSTEM AND ENDOTHELIAL MICROPARTICLES IN CHILDREN WITH HENOCH SCHONLEIN PURPURA
N. Sirachainan* (TH), W. Reakatanan, A. Chunharas, P. Kardkasam, N. Porntrasertsud, Tapaneya-Olarn, S. Treepongkarune, A. Chuansumrit

PP-MO-355 IMPROVEMENT OF PARAOXONASE 1 ACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES
R. Januszek* (PL), T. B. Domagala, M. Rzeszutko, S. Dziedzina, M. Kaczor, A. Szczeklik

PP-MO-356 PREGNANCY-ASSOCIATED ISCHEMIC STROKE: PREVALENCE AND RISK OF RECURRENT STROKE COMPARED TO NON-PREGNANT WOMEN WITH ISCHEMIC STROKE
R. H. White* (US), A. Cheema, P. Verro

PP-MO-357 INFLUENCE OF THROMBOPHILIC RISK FACTORS ON PATENCY OF PERIPHERAL ARTERIAL BYPASSES IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE – A PROSPECTIVE STUDY
R. Klamroth* (DE), S. Gottstein, C. Kubicek, M. Orlovic, I. Fritsche, H. Landgraf

PP-MO-358 PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY ENHANCES NEOINTIMA FORMATION IN A MURINE MODEL OF VEIN GRAFT DISEASE
Y. Ji* (US), W. P. Fay

PP-MO-359 STEM CELL THERAPY IN THE TREATMENT OF BUERGER’S DISEASE: A NEW AND PROSPECTIVE APPROACH
Z. Boda* (HU), K. Rázsó, M. Szarvas, M. Udvardy, Z. Oláh, P. Ilonczai, J. Tóth, L. Jámbor, T. Sipos, G. Kovács, J. Kappelmayer, K. Farkas, Z. Veréb, É. Rajnavölgyi

PP-MO-360 PREVENTION OF RECURRENT PREECLAMPSIA IN WOMEN WITH THROMBOPHILIA
A. D. Makatsariya* (RU), V. O. Bitsadze, S. M. Baimuradova, S. V. Akinshina

PP-MO-361 PREGNANCY MANAGEMENT IN WOMEN WITH HISTORY OF OBSTERIC COMPLICATIONS AND THROMBOPHILIA
A. D. Makatsariya* (RU), V. O. Bitsadze, S. M. Baimuradova, S. V. Akinshina

PP-MO-362 FACTOR VIIIC AS CARDIOVASCULAR RISK IN DM2 SUBJECTS AND CORONARY HEART DISEASE
A. Perez Cuadra* (MX), E. Cortina, R. A. Izaguirre

PP-MO-363 POLYMORPHISM (4G/5G) IN THE PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI1) PROMOTER GENE AND ITS RELATIONSHIP WITH THE PAI-1 PLASMA LEVELS IN WOMEN UNDER ORAL HORMONE REPLACEMENT THERAPY (HRT)
D. A. M. Guimarães, M. S. Santos, D. R. A. Rios, A. P. Sabino, J. E. Cardoso, K. B. Gomes, R. M. Franco, G. S. Teixeira, M. O. Sousa, L. M. S. Dusse, M. Carvalho, A. Fernandes* (BR)

PP-MO-364 ABO BLOOD GROUP, D-DIMER AND FACTOR VIII LEVELS IN POST MENOPAUSAL WOMEN USING HORMONE REPLACEMENT THERAPY
D. A. M. Guimarães, M. S. Santos, D. R. A. Rios, S. G. Paiva, J. E. Cardoso, K. B. Gomes, R. M. Franco, G. S. Teixeira, L. M. S. Dusse, M. Carvalho, A. Fernandes* (BR)

PP-MO-365 DIFFERENT METHODS OF THROMBIN GENERATION AS A PARAMETER TO MONITOR PATIENTS WITH THROMBOPHILIA AND PREGNANCY
A. Siegemund* (DE), T. Siegemund, I. Wittig, U. Scholz

PP-MO-366 OPPOSING TRENDS IN THROMBOPHILIA-INDUCED RECURRENT PREGNANCY LOSS: CONGENITAL IN CAUCASIANS, ACQUIRED IN ASIANS
A. Thiruchelvam* (MY), M. Sekaran, K. Faraizah Karim, S. Z Omar

PP-MO-367 “NON-SPECIFIC ABNORMALITIES” - A CAUSE FOR RESISTANCE IN PROTEIN C PATHWAY IN MALAYSIAN WOMEN WITH RECURRENT FAILED PREGNANCIES
A. Thiruchelvam* (MY), M. Sekaran, A. Faraizah Karim, S. Z. Omar

PP-MO-368 VARIATIONS IN THROMBOMODULIN, TISSUE FACTOR AND PROCOAGULANT PHOSPHOLIPID ACTIVITY IN EARLY AND LATE UNEXPLAINED FETAL LOSS
P. VanDreden* (FR), A. Rousseau, B. J. Woodhams, R. Favier

PP-MO-369 ELEVATED CIRCULATING SOLUBLE THROMBOMODULIN ACTIVITY, TISSUE FACTOR ACTIVITY AND PROCOAGULANT PHOSPHOLIPIDS: NEW AND USEFUL MARKERS FOR PRE-ECLAMPSIA?
A. Rousseau, R. Favier, P. van Dreden* (FR), B. J. Woodhams

PP-MO-370 PRELIMINARY RESULTS OF BASELINE THROMBIN GENERATION AND FIBRINOLYSIS IN WOMEN WITH PREVIOUS PREGNANCY-ASSOCIATED VENOUS THROMBOSIS : THROMBIN GENERATION APPEARS INCREASED AND FIBRINOLYTIC ACTIVITY REDUCED COMPARED TO HEALTHY FEMALE CONTROLS
B. Myers* (UK), N. Brook, R. Kirby

PP-MO-371 TINZAPARIN THROMBOPROPHYLAXIS FOR PROSTHETIC VALVES IN PREGNANCY
C. J. Rea* (UK), S. Rangarajan, B. J. Hunt

PP-MO-372 LOW-MOLECULAR-WEIGHT HEPARIN FOR PREVENTION OF OBSTETRIC COMPLICATIONS IN WOMEN,CARRIERS OF FACTOR V LEIDEN OR PT–G20210A MUTATION, WITH PREVIOUS EARLY OR LATE OBSTETRIC COMPLICATIONS
D. Tormene* (IT), E. Grandone, V. de Stefano, G. Palareti, G. Castaman, M. Margaglione, E. Rossi, C. Legnani, A. Tosetto, P. Simioni

PP-MO-373 ACTIVATED THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFIA) LEVELS IN HIGH PREGNANCY
D. Peetz* (DE), D. Dickemann, C. Interthal, E. Rolfes, H. Schinzel

PP-MO-374 CHANGES IN VON WILLEBRAND FACTOR AND ADAMTS-13 DURING IN VITRO FERTILIZATION
E. Westerlund* (SE), P. Henriksson, H. Wallén, O. Hovatta, K. Persdotter Eberg, F. Mobarrez, M. Blombäck, A. Antovic

PP-MO-375 FETAL AND MATERNAL THROMBOPHILIA IN IUGR WITH OR WITHOUT MATERNAL HYPERTENSIVE DISEASE
E. Biguzzi* (IT), F. Franchi, P. Pileri, P. Antonazzo, I. Cetin, P. Mannucci

PP-MO-376 TREATMENT OF VENOUS THROMBOEMBOLISM DURING PREGNANCY WITH A ONCEDAILY REGIMEN OF LMWH
F. Parent* (FR), P. Deruelle, X. Jaïs, M. Wolf, F. Jilwan, O. Sanchez, G. Meyer, G. Simonneau

PP-MO-377 MENORRHAGIA IS COMMON IN PATIENTS ON ORAL ANTICOAGULATION WITH VITAMIN-K-ANTAGONIST PHENPROCOUMON
H. Rott* (DE), G. Kappert, S. Halimeh

PP-MO-378 FOLATE DEFICIENCY STATE AND HYPERHOMOCYSTEINEMIA AS CAUSE OF ANTENATAL FETAL DEATH
I. N. Talalaeva* (RU), A. D. Makatsaria, L. N. Kiss

PP-MO-379 PREDICTIVE VALUE OF THROMBOPATH DETERMINATION IN WOMEN WITH PREGNANCY COMPLICATIONS
P. Ferroni* (IT), F. La Farina, R. Palmirotta, F. Martini, V. Raparelli, C. Nigro, S. Riondino, M. Proietti, M. Rampini, S. Basili, F. Guadagni

PP-MO-380 TNF-ALPHA GENE POLYMORPHISMS AND SUSCEPTIBILITY TO RECURRENT PREGNANCY LOSS IN ITALIAN WOMEN
R. Palmirotta, F. La Farina, P. Ferroni* (IT), G. Ludovici, C. Nigro, A. Savonarola, V. Raparelli, B. Leone, M. R. Rampini, F. Guadagni, S. Basili

PP-MO-381 ALTERED REFERENCE RANGES FOR PROTEIN C AND PROTEIN S DURING EARLY PREGNANCY: IMPLICATIONS FOR DIAGNOSIS OF THEIR DEFICIENCY DURING PREGNANCY
J. M. Said, V. Ignjatovic* (AU), P. Monagle, S. P. Walker, J. R. Higgins, S. P. Brennecke

PP-MO-382 S 35972, A NOVEL ORALLY ACTIVE THROMBIN INHIBITOR : IN VITRO AND EX VIVO ANTICOAGULANT ACTIVITY
A. Rupin* (FR), P. Mennecier, M. O. Vallez, P. Gloanec, G. de Nanteuil, T. J. Verbeuren

PP-MO-383 COAGULATION FACTOR CONCENTRATIONS ARE NOT HIGHER IN THE HEPATIC VEINS THAN IN THE PERIPHERAL CIRCULATION
A. P. A. Gadisseur* (BE), J. Schouten, S. Franque, I. Vangenechten, M. van der Planken, P. Michielsen

PP-MO-384 HYPOXIA MAY BE A STIMULUS FOR VENOUS THROMBUS RESOLUTION
C. E. Evans, J. Humphries, A. Wadoodi, M. Waltham, K. Burnand, A. Smith* (UK)

PP-MO-385 THE USE OF MRI TO FOLLOW THE FIRST 3 HOURS OF THROMBUS DEVELOPMENT IN AR-H067637 TREATED RATS
A. Ravnefjord* (SE), S. Pehrsson, A. W. Bidar, F. Risse, P. D. Hockings, M. Elg

PP-MO-386 HAEMOSTATIC RESPONSE TO IN VITRO ADDITION OF RECOMBINANT FACTOR VIIa, PROTHROMBIN COMPLEX CONCENTRATE, OR CONCENTRATE OF FACTOR IX/X IN BLOOD SPIKED WITH A DIRECT Xa INHIBITOR
J. B. Olesen, K. Christiansen, J. Ingerslev, B. Sørensen, A. Hvas* (DK)

PP-MO-387 PERMISSIVE HYPOTENSION AND DESMOPRESSIN ENHANCE CLOT FORMATION
J. B. Rezende-Neto, M. V. Andrade, J. R. Cunha-Melo, D. D. Ribeiro* (BR), T. A. Lisboa, E. R. Camargos, P. Martins, S. B. Rizoli

PP-MO-388 ENOXAPARIN DOES NOT DECREASE TOTAL MICROPARTICLES TISSUE FACTOR ACTIVITY IN AN EXPERIMENTAL MODEL OF EARLY VENOUS THROMBOSIS IN MICE
E. Ramacciotti* (US), J. A. Diaz, A. E. Hawley, D. M. Farris, N. E. Ballard, S. K. Wrobleski, D. D. Myers Jr, P. K. Henke, T. W. Wakefield

PP-MO-389 PLATELET UPREGULATION IN MICE EXPOSED TO AMBIENT PARTICULATE MATTER
F. Tablin* (US), J. W. Norris, M. Pombo, H. Auh, M. W. Lame, D. W. Wilson

PP-MO-390 PHARMACOLOGIC CHARACTARIZATION OF THE ANTIHEMOSTATIC EFFECTS OF ACYLHYDRAZONE DERIVATIVES
F. S. Frattani* (BR), E. O. Coriolano, L. M. Lima, C. A. M. Fraga, E. J. Barreiro, R. B. Zingali

PP-MO-391 EFFICACY AND SAFETY OF PROTHROMBIN COMPLEX CONCENTRATE AND RECOMBINANT ACTIVATED FACTOR VII VERSUS PLACEBO IN A RABBIT MODEL OF HEMODILUTION, BLEEDING AND THROMBOSIS: A BLIND STUDY
F. Le Sache* (FR), B. Le Bonniec, B. Dizier, A. Godier, C. Bachelot-Loza, J. Emmerich, C. M. Samama

PP-MO-392 A NOVEL MURINE HEMOSTASIS MODEL: STUDIES ON RECOMBINANT FACTOR VIIa AND NN1731
H. C. Whinna* (US), D. M. Monroe

PP-MO-393 NDRG4-NULL MICE ARE VULNERABLE TO CEREBRAL ISCHEMIA
H. Yamamoto* (JP), K. Kokame, H. Yanamoto, T. Okuda, Y. Nakajo, S. Miyamoto, T. Miyata

PP-MO-394 ORAL SYSTEMIC ADMINISTRATION OF ANKAFERD BLOOD STOPPER HAS NO SHORT-TERM TOXICITY IN AN IN VIVO RABBIT EXPERIMENTAL MODEL
H. Bilgili, O. Captug, A. Kosar, M. Kurt, M. Kekilli, A. Shorbagi, O. K. Kurt, O. Ozdemir, H. Goker, I. C. Haznedaroglu* (TR)

PP-MO-395 THE DIRECT ORAL THROMBIN INHIBITOR S 35972 IS ANTITHROMBOTIC IN THE MICROVASCULATURE OF MICE
I. Marx* (FR), M. O. Vallez, J. Paysant, G. de Nanteuil, A. Rupin, T. J. Verbeuren

PP-MO-396 PHARMACOEQUIVALENCE OF ENOXAPARIN AND CONTAMINATED ENOXAPARIN AS STUDIED IN ANIMAL MODELS OF BLEEDING AND THROMBOSIS
J. Kuziej* (US), W. Jeske, D. Hoppensteadt, E. Litinas, E. McGeehan, J. Fareed, R. Kennedy

PP-MO-397 IS THE APTT OR ANTI-Xa A MORE RELIABLE MEASURE OF HEPARIN ANTICOAGULATION IN THE ACUTE PHASE RESPONSE?
J. Uprichard* (UK), R. A. Manning, A. Hann, M. A. Laffan

PP-MO-398 URBAN AND DIESEL PARTICULATE MATTER INDUCE LUNG INFLAMMATION BUT POOR SECONDARY HEMOSTASIS ACTIVATION IN MICE
J. Emmerechts* (BE), B. Nemery, M. Hoylaerts

PP-MO-399 IMMUNOGENICITY OF LOW MOLECULAR WEIGHT HEPARINS AND BIOSIMILARS
J. M. Walenga* (US), D. Hoppensteadt, J. Cunanan, W. P. Jeske, C. Adiguzel, M. Bakhos

PP-MO-400 THROMBOGENESIS WITH CONTINUOUS BLOOD FLOW IN THE INFERIOR VENA CAVA: A NOVEL MOUSE MODEL
J. A. Diaz* (US), A. E. Hawley, A. M. Berguer, S. K. Wrobleski, B. R. Lucchesi, D. D. Myers Jr

PP-MO-401 EFFECTS OF 7 kDa STREPTOKINASE FRAGMENT: THE RABBIT MODEL OF HAEMOSTASIS SYSTEM
S. P. Gavrylyuk* (UA), O. M. Savchuk, G. L. Volkov, L. I. Ostapchenko

PP-MO-402 HIGHLIGHTING IN VITRO HYPERCOAGULABILITY DURING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION WITH ENDOTHELIAL DYSFUNCTION
A. Brunette* (FR), J. Max, V. Regnault, A. Benetos, T. Lecompte, D. Wahl, F. Chabot

PP-MO-403 DERIVATION OF A MODEL FOR PREDICTING THE WARFARIN MAINTENANCE DOSE IN PATIENTS WITH VENOUS THROMBOEMBOLISM BASED ON THE RESPONSE TO A STANDARDIZED INITIATION NOMOGRAM
A. Lazo-Langner* (CA), K. Monkman, M. J. Kovacs

PP-MO-404 QUALITY OF TELEPHONE-BASED MANAGEMENT OF ORAL ANTICOAGULATION TREATMENT
M. Gubensek, A. Mavri* (SI)

PP-MO-405 URINARY PROTHROMBIN FRAGMENT 1.2 (UF1.2) LEVELS IN PREGNANCIES COMPLICATED BY PREECLAMPSIA
A. S. Andersen* (DK), T. Bergholt, C. Sørensen, I. Deltour, J. G. Berthelsen, M. R. Lassen

PP-MO-406 EFFICACY OF 3-MG WARFARIN LOADING DOSE ON TIME TO THERAPEUTIC INR IN ADULT THAI PATIENTS
B. Suwanawiboon* (TH), P. Kongtim, Y. Chinthammitr, T. Ruchutrakool, W. Wanachiwanawin

PP-MO-407 EFFECTS OF AGE AND GENDER ON THE SINGLE-DOSE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF APIXABAN
C. E. Frost* (US), S. Nepal, Y. Barrett, F. Lacreta

PP-MO-408 LONG-TERM TREATMENT WITH AN ORAL DIRECT THROMBIN INHIBITOR CHANGES THE PATTERN OF INFLAMMATORY MARKERS IN PATIENTS WITH MYOCARDIAL INFARCTION
C. Christersson* (SE), J. Oldgren, L. Wallentin, A. Siegbahn

PP-MO-409 HOW USEFUL IS DETERMINATION OF ANTI FACTOR Xa ACTIVITY TO GUIDE BRIDGING THERAPY WITH ENOXAPARIN? A PILOT STUDY
C. Hammerstingl* (DE), H. Omran, B. Pötzsch

PP-MO-410 AN EVALUATION OF THROMBOTIC CHANGES IN BEREAVEMENT
M. C. Morel-Kopp, T. Buckley, Q. Chen, G. Tofler, S. McKinley, R. Bartrop, C. M. Ward* (AU)

PP-MO-411 LONG TERM EFFECT OF TOMATO JUICE AND FISH OIL ON PLATELET FUNCTION AND THROMBUS FORMATION
M. C. Morel-Kopp, B. McEwen, Q. Chen, C. M. Ward* (AU)

PP-MO-412 ANTI-HUMAN, ANTI-BOVINE THROMBIN ANTI-BODIES AND FACTOR V/Va ANTIBODIES IN NORMAL HUMAN SUBJECTS
C. Paterson* (US), J. Fareed

PP-MO-413 EFFICACY AND SAFETY OF LONG TERM ADMINISTRATION OF BEMIPARIN IN PATIENTS WHO NEED CRONIC ANTICOAGULATION AND HAVE SUFFERED SEVERE AND RECURRENT GASTROINTESTINAL BLEEDING
E. Marti* (ES), J. Mateo, A. Santamaria, J. C. Souto, C. Alvarez, C. Villanueva, J. Fontcuberta

PP-MO-414 SUPERVISED PATIENT SELF-TESTING OF WARFARIN THERAPY USING AN INTERNET BASED EXPERT SYSTEM - A FOLLOW UP STUDY
F. Ryan, S. Byrne, S. Oshea* (IE)

PP-MO-415 FONDAPARINUX VERSUS LEPIRUDIN IN THE MANAGEMENT OF PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) WITH OR WITHOUT THROMBOSIS (ON BEHALF OF THE FLHIT STUDY INVESTIGATORS)
F. Piovella* (IT), M. Barone, C. Beltrametti, C. Piovella, S. Barco, M. de Amici, A. D’Angelo

PP-MO-416 LIMITED UTILITY OF PLATELET-THROMBIN ACTIVATION MARKERS IN THE ASSESSMENT OF PATIENTS WITH CHEST PAIN OR SUSPICION OF VENOUS THROMBOEMBOLISM
S. El Ghannudi, S. Gayol, T. Kirchgesner, M. L. Wiesel, O. Morel, L. Calvel, P. Bareiss, J. Kopferschmitt, J. P. Cazenave, P. Ohlmann, C. Gachet, F. Lanza* (FR)

PP-MO-417 EFFICACY AND SAFETY OF FONDAPARINUX IN THE INITIAL TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MODERATE RENAL IMPAIRMENT (MRI)
H. R. Buller* (NL)

PP-MO-418 ASSESSING IMMUNE RESPONSE AFTER REPEATED AVIDIN REVERSAL OF THE ANTI-Xa ACTIVITY OF IDRABIOTAPARINUX (BIOTINYLATED IDRAPARINUX)
I. Paty* (FR), P. Cortez, M. Trellu, E. Sultan

PP-MO-419 NEW ASSAYS FOR MEASURING DIRECT THROMBIN INHIBITORS ON PLASMA
J. J. Amiral* (FR), A. M. Vissac, M. Peyrafitte

PP-MO-420 IDENTIFICATION OF COAGULATION PARAMETERS WHICH DETERMINE THE COMBINED EFFECT OF LOW-MOLECULAR-WEIGHT HEPARIN CERTOPARIN AND PHENPROCOUMON IN PATIENTS UNDERGOING CARDIOVERSION FOR RECENT ATRIAL FIBRILLATION
J. Harenberg* (DE), J. Wierdak, C. Giese, C. Weiss, C. Abletshauser, U. Tebbe

PP-MO-421 WHICH BIOLOGICAL TEST BETTER REFLECTS THE POTENTIAL HEMORRHAGIC RISK ASSOCIATED WITH STACK-ON UNFRACTIONATED HEPARIN: RESULTS FROM THE STACKENOX STUDY
L. Drouet* (FR), C. Bal Dit Sollier, J. Martin

PP-MO-422 PREVENTION OF VENOUS THROMBOSIS IN CANCER PATIENTS: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING TWO DIFFERENT DOSAGES OF LOW-MOLECULAR WEIGHT HEPARIN
L. Traby* (AT), A. Kaider, R. Schmid, A. Kranz, P. Quehenberger, P. A. Kyrle, S. Eichinger

PP-MO-423 IN VIVO TAFI ACTIVATION IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY (OPCAB): EFFECT OF DIFFERENT HEPARIN DOSAGES AND CORRELATION WITH THROMBIN AND PLASMIN GENERATION
M. Colucci* (IT), F. Semeraro, C. T. Ammollo, D. Paparella, G. Scrascia, C. Fondacone, N. Semeraro

PP-MO-424 EFFICACY OF EARLY ANTITHROMBOTIC TREATMENT IN RETINAL VEIN OCCLUSION
A. Donà, M. T. Sartori, S. Piermarocchi, E. Pilotto, L. Pasetto, A. Pagnan, P. Prandoni* (IT)

PP-MO-425 INFERIOR VENA CAVAL FILTER INSERTION – 5 YEAR EXPERIENCE IN A TERTIARY CARE HOSPITAL
J. Saour* (SA), M. El Sherif, A. Al Harthi, E. Bakhsh, L. Mammo

PP-MO-426 FILTER FRACTURE AND MIGRATION OF A GUNTHER TULIP RETRIEVABLE INFERIOR VENA CAVA FILTER 22 DAYS AFTER IN A PEDIATRIC PATIENT: A CASE REPORT
J. Y. K. Yang* (CA), A. K. C. Chan, L. R. Brandao, S. Williams

PP-MO-427 ARTERIOVENOUS (AV) FISTULA THROMBOSIS AND THROMBOPHILIA
J. I. Varughese* (US), M. Sandhu, S. Sachdev, S. Palekar, A. Cohen, A. Eisenberger

PP-MO-428 IMMOBILIZATION OF CORN TRYPSIN INHIBITOR REDUCES THE IN VITRO PROCOAGULANT PROPERTIES OF CATHETERS
J. W. Yau* (CA), A. R. Stafford, J. C. Fredenburgh, J. L. Brash, J. I. Weitz

PP-MO-429 IMPACT OF IN VIVO PLATELET ACTIVITY ON SUBCLINICAL STENT THROMBOSIS: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
K. Komukai* (JP), A. Tanaka, H. Kitabata, T. Tanimoto, S. Takarada, N. Nakamura, K. Hirata, M. Mizukoshi, T. Imanishi, T. Akasaka

PP-MO-430 REAL TIME MEASURMENTS OF COAGULATION ON BACTERIAL CELLULOSE
L. Faxälv* (SE), H. Fink, B. Risberg, P. Gatenholm, T. L. Lindahl, A. Sellborn

PP-MO-431 PROGNOSTIC ROLE OF HYPERHOMOCYSTEINEMIA IN PATIENTS UNDERGOING CORONARY STENT IMPLANTATION
O. A. Smirnova* (RU), V. M. Shmeleva, L. P. Papayan, S. A. Boldueva

PP-MO-432 HAEMOPHILIA AND INVASIVE CORONARY PROCEDURES
R. Santoro* (IT), S. Prejanò, P. Iannaccaro, G. Muleo

PP-MO-433 A HISTORY OF LATE STENT THROMBOSIS IS NOT ASSOCIATED WITH INCREASED ACTIVATION OF THE CONTACT PHASE SYSTEM
V. Pönitz* (NO), J. W. P. Govers-Riemslag, H. ten Cate, R. van Oerle, P. Næsgaard, H. Grundt, D. Pritchard, A. Larsen, D. W. T. Nilsen

PP-MO-434 INCREASED LEVELS OF VON WILLEBRAND FACTOR MULTIMERS AND VWFCLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEONATES
T. Strauss, A. Zivelin, B. Ravid, A. Lubetsky* (IL), I. Morag, J. Kuint, G. Kenet

PP-MO-435 DEVELOPMENT OF A PEDIATRIC QUALITY OF LIFE INVENTORY FOR CHILDREN REQUIRING LONG-TERM ANTICOAGULATION
A. A. K. Bruce* (CA), M. E. Bauman, A. S. Newton, M. Bauman, L. Bajzar, K. Black, L. Legge, M. Massicotte

PP-MO-436 INCIDENCE OF THROMBOTIC AND BLEEDING COMPLICATIONS DURING CARDIAC CATHETERIZATION IN CHILDREN (HEARTCAT-STUDY)
A. Hanslik* (AT), E. Kitzmüller, M. Haumer, H. Karapetian, K. Thom, U. Salzer-Muhar, I. Michel-Behnke, C. Male

PP-MO-437 THROMBIN GENERATION IN CHILDREN ON ORAL ANTICOAGULANTS
A. Greenway* (AU), V. Ignjatovic, R. Summerhayes, F. Newall, J. Burgess, L. Derosa, P. Monagle

PP-MO-438 EVALUATION OF POINT OF CARE INR IN CHILDREN
A. L. Greenway* (AU), V. Ignjatovic, R. Summerhayes, F. Newall, J. Burgess, L. Derosa, P. T. Monagle

PP-MO-439 EFFECTS OF L-ASPARAGINASE THERAPY ON THROMBIN GENERATION IN CHILDREN WITH ACUTE LEUKEMIA
A. Yamashita* (JP), C. Nagae, T. Shoji, S. Muto, M. Asahara, M. Morimoto, K. Kondo, A. Kinoshita, S. Yamazaki, S. Takayama, M. Taki

PP-MO-440 THROMBOCYTOPENIA ASSOCIATED MULTIPLE ORGAN FAILURE IN AN INFANT - A CHALLENGING CASE
A. Unuvar* (TR), D. Demirkol, A. Nayir, M. Karabocuoglu, D. Yanni, O. Devecioglu

PP-MO-441 EVALUATION OF THROMBOTIC EFFECTS OF ASPARAGINASE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
C. Pawlik* (BE), A. Demulder, P. Lê, A. Ferster

PP-MO-442 CONCURRENT PAS AND CSVT IN THE NEWBORN
D. Telega, S. Ong, O. O. Zaidat, C. Amlie-Lefond* (US)

PP-MO-443 MAJOR BLEEDING COMPLICATIONS IN PEDIATRIC MECHANICAL VALVE PATIENTS DURING BRIDGING ANTICOAGULATION THERAPY
C. I. Segbefia* (CA), S. Williams, L. Brandao

PP-MO-444 CATHETER-RELATED THROMBOSIS AND INFECTION IN CHILDREN WITH LONG-TERM TOTAL PARENTERAL NUTRITION
I. L. Vegting, M. M. Tabbers, M. A. Benninga, C. H. van Ommen* (NL)

PP-MO-445 A CLINICAL CASE OF HEMOGLOBIN C DISEASE, PROTEIN S DEFICIENCY AND LEUKEMIA
D. Aïtchafa Tadlaoui* (DZ), C. Touchrift, Z. Guechi

PP-MO-446 ADAMTS-13 ACTIVITY IS DECREASED IN CHILDREN WITH BETA-THALASSEMIA
D. Sosothikul* (TH), P. Kuwatjanakul, Y. Kittikalayawong, C. Bubpachart, P. Seksarn

PP-MO-447 VENOUS STASIS ULCER IN PAEDIATRIC POST PHLEBITIC SYNDROME MULTIDISCIPLINARY MANAGEMENT OF A CHRONIC CONDITION
D. Castle* (CA), L. Brandao, S. Williams

PP-MO-448 PROTEIN C REPLACEMENT DURING FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS WITH CANCER
P. Giordano, V. Cecinati, M. Grassi, L. P. Brescia, G. C. Del Vecchio, F. de Leonardis, G. Arcamone, N. Santoro, D. de Mattia* (IT)

PP-MO-449 AGE-RELATED DIFFERENCES IN IN VIVO UFH RESPONSE IN CHILDREN
F. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, P. Monagle

PP-MO-450 ANTI-Xa:ANTI-IIa RATIO VARIES WITH AGE AND UFH CONCENTRATION IN CHILDREN
F. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, P. Monagle

PP-MO-451 CORRELATION OF UFH MEASURES OF EFFECT WITH PROTAMINE TITRATION IN CHILDREN
F. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, P. Monagle

PP-MO-452 PAEDIATRIC THROMBOSIS IN KENYA
G. W. Kitonyi* (KE), J. W. Githanga, J. A. Rajab, W. O. Mwanda

PP-MO-453 THROMBOPHILIA IN CHILDREN
L. Lokar* (SI), V. Urlep ?alinoviæ, O. Krajnc, L. ?olman

PP-MO-454 EMPOWARMENT: EDMONTON PEDIATRIC WARFARIN SELF-MANAGEMENT STUDY
M. E. Bauman* (CA), K. L. Black, M. L. Bauman, S. Kuhle, L. Bajzar, M. P. Massicotte

PP-MO-455 ENOXAPARIN MONITORING: CHALLENGES OF CENTRAL LINE BLOOD SAMPLES
M. P. Massicotte* (CA), M. E. Bauman, K. L. Black, L. Bajzar

PP-MO-456 CHALLENGES OF ANTICOAGULATION THERAPY IN CHILDREN: UFH CONTAMINATION OF ENOXAPARIN ANTI Xa LEVELS WHEN DRAWN THROUGH A CENTRAL LINE
M. P. Massicotte* (CA), M. E. Bauman, M. L. Bauman, K. L. Black, L. Bajzar

PP-MO-457 COMPUTER ASSISTED VKA MONITORING WITH POINT OF CARE DEVICE BY GENERAL PRACTITIONERS
M. Basileo, E. Filippucci, S. Iaboni, P. Grilli, M. Vecchioli, G. Agnelli, A. Iorio* (IT)

PP-MO-458 PROSPECTIVE ASSESSMENT OF CLINICAL ENDPOINTS OF VKA TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL
A. Iorio* (IT), E. Filippucci, M. Basileo, S. Iaboni, E. Paccamiccio, M. Vecchioli, G. Agnelli

PP-MO-459 PSYCHOSOCIAL OUTCOME IN PARENTS OF CHILDREN WITH HAEMOPHILIA
S. Wiedebusch, B. Siegmund* (DE), H. Pollmann, F. Muthny

PP-MO-460 CURRICULUM DEVELOPMENT IN THROMBOSIS MEDICINE
C. Gonsalves* (CA), P. Wells, A. Karovitch, L. Varpio, M. Marks, M. Rodger

PP-MO-461 STRUCTURED MANAGEMENT OF ORAL ANTICOAGULANT THERAPY BY GENERAL PRACTITIONERS
C. Manotti* (IT), C. Pattacini, R. Emanuele

PP-MO-462 EVALUATING THE FEASIBILITY OF LESS FREQUENT INR TESTING DURING CHRONIC ANTICOAGULATION THERAPY
D. M. Witt* (US), T. Delate, N. P. Clark, M. A. Crowther, D. A. Garcia, W. Ageno, E. M. Hylek

PP-MO-463 INCIDENCE AND PREDICTORS OF SERIOUS BLEEDING FOLLOWING POLYPECTOMY IN PATIENTS RECEIVING AND NOT RECEIVING ORAL ANTICOAGULATION THERAPY
D. M. Witt* (US), T. Delate, K. H. McCool, M. Dowd, N. P. Clark, M. A. Crowther, D. A. Garcia, W. Ageno, F. Dentali, E. M. Hylek, W. G. Rector

PP-MO-464 QUALITY OF ORAL ANTICOAGULATION MANAGEMENT IN PHARMACIST VS NURSE MANAGED MODELS OF CARE
E. A. Nutescu* (US), A. Bautista, W. Gao, T. Stamos, W. Galanter, J. Garofalo, J. Bauman

PP-MO-465 ENOXAPARIN IS COST-SAVING COMPARED WITH UNFRACTIONATED HEPARIN (UFH) FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH ACUTE ISCHEMIC STROKE: AN ANALYSIS OF HOSPITAL COSTS FROM THE PREVAIL TRIAL
G. Pineo* (CA), J. Lin, L. Stern, T. Subrahmanian

PP-MO-466 ENOXAPARIN FOR VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN PATIENTS WITH ACUTE ISCHEMIC STROKE IS ASSOCIATED WITH LOWER COSTS TO THE PAYERS THAN UNFRACTIONATED HEPARIN (UFH): ANALYSIS FROM THE PREVAIL TRIAL
G. Pineo* (CA), J. Lin, L. Stern, T. Subrahmanian

PP-MO-467 PERFORMANCE OF A LOW-VOLUME COAGULATION ANALYZER WITH EXPANDED TEST MENU
M. Sonnek, H. Su, G. A. Cutsforth* (US)

PP-MO-468 ECONOMIC COMPARISON OF RIVAROXABAN WITH ENOXAPARIN IN CANADIAN PATIENTS UNDERGOING TOTAL HIP AND TOTAL KNEE REPLACEMENT
P. Wells, A. Diamantopoulos, H. McDonald* (CA), F. Forster, M. Lees

PP-MO-469 INTERIM ANALYSIS OF TRIPLE INTERVENTION TO IMPROVE INR CONTROL IN WARFARIN-TREATED PATIENTS
H. I. Bussey* (US), M. B. Walker, K. L. Bussey Smith, C. Frei

PP-MO-470 INFREQUENT USE OF EMPIRIC ANTICOAGULATION OR FIBRINOLYSIS FOR SEVERE ACUTE PULMONARY EMBOLISM
J. A. Kline* (US), B. Hiestand, D. Slattery, D. Schreibner, D. Schreibner, R. Pendleton

PP-MO-471 ARNICA MONTANA HAS NO EFFECT ON COAGULATION AND BLEEDING TIME IN VIVO
J. N. Mahlangu* (ZA), J. N. Mahlangu, B. Saunders, A. Reaves, T. Nkujani, M. Basson

PP-MO-472 MAINTAINED IMPACT OF AN ELECTRONIC ALERT SYSTEM FOR VENOUS THROMBOEMBOLISM PREVENTION AMONG HOSPITALIZED PATIENTS: 3-YEAR EXPERIENCE
R. Lecumberri, M. Marqués, E. Panizo, P. Rodríguez-Otero, C. Pegenaute, A. García-Mouriz, J. A. Páramo* (ES)

PP-MO-473 REAL-WORLD PATTERNS OF ARGATROBAN OR LEPIRUDIN USE IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA
A. F. Shorr, R. V. Horblyuk* (US), A. Basu, M. D. Zilberberg

PP-MO-474 DIC AND THROMBOPHILIA PROPHYLAXIS DURING CHEMOTHERAPY IN GYNECOLOGIC CANCER PATIENTS
A. Vorobev* (RU), A. Makatsaria

PP-MO-475 TICK INHIBITORS MODULATING BLOOD CLOTTING AND CELL PROLIFERATION
A. M. Chudzinski-Tavassi* (BR), P. L. De-Sá-Júnior, S. M. Simons, D. G. L. Oliveira, J. S. Ventura, F. Faria, I. F. C. Batista, E. M. Reis

PP-MO-476 HEMOSTATIC VARIABLES IN CANCER PATIENTS RECEIVING LOW-MOLECULARWEIGHT HEPARIN (LMWH) NADROPARIN OR PLACEBO DURING CHEMOTHERAPY IN THE PROTECHT TRIAL
A. Falanga* (IT), A. Vignoli, M. Marchetti, M. Mandalà, L. Russo, M. Kauling, G. Agnelli, C. Bianchini, and the PROTECHT Study Group

PP-MO-477 INCREASED THROMBIN GENERATION IN LUNG CANCER PATIENTS IS PARTIALLY REVERSED BY SURGICAL RESECTION AND ENOXAPARIN PROPHYLAXIS
C. Papageorgiou* (FR), E. Marret, Y. Ynineb, F. Bonnet, I. Elalamy, G. T. Gerotziafas

PP-MO-478 EFFECT OF POST-OPERATIVE PROPHYLAXIS WITH ENOXAPARIN ON THOMBOELASTOGRPHIC PROFILE OF PATIENTS WITH LUNG CANCER
C. Papageorgiou* (FR), E. Marret, Y. Ynineb, F. Bonnet, G. T. Gerotziafas, I. Elalamy

PP-MO-479 LOW MOLECULAR WEIGHT HEPARIN DOWNREGULATES TISSUE FACTOR EXPRESSION AND SUPPRESSES PANCREATIC CANCER CELL INVASION IN VITRO
C. Ettelaie* (UK), A. Maraveyas, M. E. W. Collier

PP-MO-480 GENETIC POLYMORPHISMS IN CLOTTING FACTORS AND THE RISK OF COLORECTAL CANCER
C. Y. Vossen* (NL), M. Hoffmeister, J. Chang-Claude, F. R. Rosendaal, H. Brenner

PP-MO-481 LEPTIN ENHANCES TISSUE FACTOR SYNTHESIS IN THE HUMAN BREAST CANCER CELL LINE MCF7
E. Napoleone* (IT), A. Cutrone, F. Zurlo, G. Colavecchia, M. Latella, L. Iacoviello, G. de Gaetano, M. B. Donati, R. Lorenzet

PP-MO-482 CALIBRATED AUTOMATED THROMBOGRAM (CAT) IS A SUITABLE AND USEFUL ASSAY FOR IDENTIFICATION AND CHARACTERIZATION OF THE PROCOAGULANT ACTIVITY (PCA) OF TUMOR CELLS
E. Diani* (IT), M. Marchetti, E. Cantalino, H. ten Cate, A. Falanga

PP-MO-483 A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS FOR DEEP-VEIN THROMBOSIS PROPHYLAXIS ENOXAPARIN VERSUS NO INTERVENTION IN ONCOLOGY PATIENTS FOLLOWING SURGERY IN BRAZIL
E. de Meis* (BR), L. Schluckebier, R. A. Fernandes, E. Bernardina, R. A. Levy, F. F. Quintella

PP-MO-484 COAGULATION PROTEINS IN HEALTHY VERSUS MALIGNANT COLON TISSUE
G. L. van Sluis* (NL), H. M. H. Spronk, R. van Oerle, J. Westerga, H. ten Cate, J. M. M. B. Otten

PP-MO-485 CANCER CELL-DERIVED MICROPARTICLES ACCELERATE THROMBUS FORMATION IN VIVO
G. M. Thomas* (FR), L. Panicot-Dubois, D. Lombardo, C. Dubois

PP-MO-486 MOLECULAR PATHWAYS INVOLVED IN THROMBUS FORMATION INDUCED BY CANCER CELL-DERIVED MICROPARTICLES IN VIVO
G. M. Thomas* (FR), C. Dubois, R. Lacroix, F. Dignat-George, D. Lombardo, L. Panicot-Dubois

PP-MO-487 LOW RISK FOR SYMPTOMATIC VENOUS THROMBOEMBOLIC EVENTS (VTE) DURING CYTOKINE ADMINISTRATION FOR PERIPHERAL BLOOD STEM CELL MOBILIZATION
H. V. K. Naina* (US), R. K. Pruthi, D. J. Inwards, M. R. Litzow, S. M. Ansell, D. Angela, W. J. Hogan, M. A. Gertz, D. A. Gastineau, M. A. Elliott, G. S. Nowakowski, S. K. Kumar

PP-MO-488 VENOUS THROMBOEMBOLISM (VTE) IN HOSPITALIZED CANCER PATIENTS: PROPHYLAXIS FAILURE OR FAILURE TO PROPHYLAX !
H. N. Abdel-Razeq, F. A. Badainh* (JO), I. M. Treish, A. H. Mansour

PP-MO-489 A MECHANISM FOR THROMBIN-DEPENDENT LUNG METASTASIS IN PATIENTS WITH OSTEOSARCOMA
K. S. Borensztajn* (NL), H. Aberson, A. P. Groot, M. P. Peppelenbosch, A. Spek

PP-MO-490 THE CHEMOTHERAPEUTIC METABOLITE ACROLEIN MODULATES PRO- AND ANTICOAGULANT PATHWAYS ON ENDOTHELIAL AND SMOOTH MUSCLE CELLS
L. L. Swystun* (CA), P. C. Liaw

PP-MO-491 EFFECT OF L-ASPARAGINASE ADMINISTRATION ON TISSUE FACTOR,THROMBOMODULIN ACTIVITY AND PROCOAGULANT PHOSPHOLIPIDS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
A. Rousseau, P. Schneider, P. Vandreden, J. Vannier, B. J. Woodhams, M. Vasse* (FR)

PP-MO-492 VENOUS THROMBOEMBOLISM AND BLEEDING IN CANCER PATIENTS ON BEVACIZUMAB THERAPY: A META-ANALYSIS
N. M. Kuderer* (US), T. L. Ortel, C. W. Francis, A. A. Khorana, M. S. Poniewierski, G. H. Lyman

PP-MO-493 VENOUS THROMBOEMBOLISM COMPLICATING MALIGNANCY:EFFECT OF TUMOUR SUBTYPE AND THROMBOTIC LOAD ON SURVIVAL
T. Prestidge, S. Lee, L. Young, P. Harper, P. A. Ockelford* (NZ)

PP-MO-494 ELEVATED LEVELS OF FVIIa-AT FOLLOWING PREDNISONE MONOTHERAPY IN CHILDREN WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA
U. Athale* (CA), T. Nayiager, J. McGrath, A. Moghrabi, A. Chan

PP-MO-495 PREVALENCE OF HYPERHOMOCYSTEINEMIA IN PATIENTS WITH MULTIPLE MYELOMA
V. M. Shmeleva* (RU), L. P. Papayan, K. M. Abdulkadirov

PP-MO-496 USEFULNESS OF VENOMETER TEST IN OUTPATIENT WITH CLINICAL SUSPICION OF DEEP VEIN THROMBOSIS
A. Alatri* (IT), O. Paoletti, L. Bassi, A. Zimmermann, E. Spotti, N. Delpero, S. Testa

PP-MO-497 CUT-OFF LEVEL OF SOLUBLE FIBRIN FOR DIAGNOSING VENOUS THROMBOEMBOLISM USING NANOPIA®SF
A. Suzuki* (JP), H. Yago, H. Wada, T. Matsumoto, N. Yamada, A. Sudo, T. Nobori

PP-MO-498 COMPARISON OF THE WELLS SCORE WITH THE SIMPLIFIED REVISED GENEVA SCORE FOR ASSESSING PRETEST PROBABILITY OF PULMONARY
A. Penaloza* (BE), C. Melot, S. Motte

PP-MO-499 “COCKADE THROMBUS”, A NEW ULTRASOUND DIAGNOSIS
M. Maufus, G. Le Gal, P. Quehe, A. Delluc* (FR), L. Bressollette

PP-MO-500 ”COCKADE” THROMBOSIS OF LOWER LIMBS IS ASSOCIATED WITH REDUCED OCCURRENCE OF SYMPTOMATIC PULMONARY EMBOLISM
A. Delluc* (FR), P. Quehe, E. Plat, M. Maufus, G. Le Gal, K. Lacut, E. Oger, D. Mottier, L. Bressollette

PP-MO-501 PERFORMANCE OF FIVE D-DIMER ASSAYS IN THE DIAGNOSIS OF SYMPTOMATIC DISTAL LEG VEIN THROMBOSIS
B. Luxembourg* (DE), J. Schwonberg, C. Hecking, M. Schindewolf, D. Zgouras, S. Lehmeyer, E. Lindhoff-Last

PP-MO-502 PERFORMANCE CHARACTERISTICS OF A NEW AUTOMATED LATEX IMMUNOTURBIDIMETRIC ASSAY FOR DETERMINING D-DIMER CONCENTRATIONS IN HUMAN PLASMA
C. Silverstrim* (US), C. J. Hoecke, R. S. Greenfield, E. A. Lazarski, H. J. L. Fryer

PP-MO-503 IMPROVEMENT OF THE SPECIFICIY AND DIAGNOSTIC UTILITY OF A D- DIMER (DD) TEST FOR DEEP VEIN THROMBOSIS (DVT) EXCLUSION USING DIFFERENT CUT-OFF LEVELS ACCORDING TO AGE AND GENDER
C. Legnani* (IT), M. Cini, M. Poggi, C. Abate, E. Favaretto, L. Piscitelli, G. Guazzaloca, G. Palareti

PP-MO-504 MULTICENTER EVALUATION OF A NEW QUANTITATIVE HIGHLY SENSITIVE LATEX DDIMER ASSAY IN PATIENTS WITH CLINICALLY SUSPECTED VENOUS THROMBOEMBOLISM (VTE)
C. Legnani* (IT), M. Cini, D. Scarvelis, P. Toulon, J. Wu, G. Palareti

PP-MO-505 PREDICTION RULES FOR PULMONARY EMBOLISM: A META-ANALYSIS
E. Ceriani* (CH), C. Combescure, G. Le Gal, T. Perneger, H. Bounameaux, A. Perrier, M. Righini

PP-MO-506 UTILITY OF D-DIMER TESTING IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY EMBOLISM AND IMPAIRED RENAL FUNCTION
F. A. Klok* (NL), R. Karami-Djurabi, J. Kooiman, S. I. Velthuis, M. Nijkeuter, M. V. Huisman

PP-MO-507 RIGHT VENTRICULAR REMODELING BY AND POTENTIAL USE OF CARDIAC MRI IN THE CLINICAL FOLLOW-UP OF PATIENTS WITH ACUTE PULMONARY EMBOLISM
F. A. Klok* (NL), S. Romeih, J. J. M. Westenberg, L. J. M. Kroft, A. de Roos, M. V. Huisman

PP-MO-508 EVALUATION OF VENTILATION AND PERFUSION LUNG SPECT (SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY) IN THE DIAGNOSIS OF PULMONARY EMBOLISM: PRELIMINARY RESULTS BASED ON 100 CASES
S. Querellou, P. Guillo, F. Couturaud, P. Salaun, G. Le Gal* (FR), K. Lacut, E. Oger, C. Leroyer, D. Mottier, A. Le Duc-Pennec

PP-MO-509 NON-IMPLEMENTATION OF GUIDELINE RECOMMENDATIONS FOR DIAGNOSIS OF DEEP VENOUS THROMBOSIS IN GERMANY
H. E. Gerlach* (DE), S. M. Schellong, V. Hach-Wunderle, E. Rabe, H. B. Riess, H. Carnarius, S. Eberle, R. M. Bauersachs

PP-MO-510 PRO275SER HOMOZYGOUS MUTATION OF PROC GENE CAUSES TYPE II INHERITED PROTEIN C DEFICIENCY
J. Wang* (CN), J. Dai, Q. Fu, T. Yu, X. Wang, H. Wang

PP-MO-511 COMPOUND HETEROZYGOUS MUTATIONS IN THE PROS1 GENE RESPONSIBLE FOR QUANTITATIVE AND QUALITATIVE PROTEIN S DEFICIENCY
J. Yamanouchi* (JP), T. Hato, H. Fujiwara, Y. Yakushijin, M. Yasukawa

PP-MO-512 ANTICOAGULATION PRIOR TO DIAGNOSTIC CONFIRMATION IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM
M. R. Marchick* (US), D. M. Courtney, C. Kabrhel, C. L. Moore, K. E. Nordenholz, J. A. Kline

PP-MO-513 ANTITHROMBIN DEFICIENCY: A GAP IN DIAGNOSTICS
R. Fischer* (DE), K. Heidinger, A. Huth,Kühne, P. Staritz, R. Zimmermann, A. Pavlova, J. Oldenburg, B. Kemkes,Matthes

PP-MO-514 EVALUATION OF THE COMBINATION OF D-DIMER AND SOLUBLE FIBRIN DETERMINATIONS IN PATIENTS WITH SUSPECTED VENOUS THROMBO-EMBOLISM
S. Mirshahi* (FR), C. Soria, B. Kouchakji, G. Kierzek, J. Borg, L. Drouet, D. Elkharrat, R. Varin, J. Chidiac, M. Grimaux, C. Parry, B. J. Woodhams, J. Soria

PP-MO-515 A NEGATIVE IMMUNOTURBIDOMETRIC D-DIMER AS A STAND-ALONE TEST EXCLUDES PULMONARY EMBOLISM
S. M. Bates* (CA), C. Kearon, J. A. Julian, J. Douketis, S. Schulman, B. MacKinnon, S. Parpia, J. S. Ginsberg

PP-MO-516 PREOPERATIVE SCREENING USING VENOUS DUPLEX SCANNING DOES NOT ALTER THE OUTCOME IN PATIENTS AT HIGH RISK OF POSTOPERATIVE VENOUS THROMBOEMBOLISM
T. Yamaki* (JP), H. Sakurai, K. Soejima, T. Kono, A. Hamahata

PP-MO-517 FATAL POST SPLENECTOMY PULMONARY EMBOLISM IN MILD HAEMOPHILIA. A REPORT OF A CASE
A. Davoodabadi* (IR), B. Keleidari

PP-MO-518 FUNCTIONAL MRI TECHNIQUES AS EARLY DIAGNOSTIC MARKERS IN HEMOPHILIC ARTHROPATHY
A. Amirabadi* (CA), E. Miller, H. Gahunia, S. A. F. Peel, A. Zhong, R. Weiss, G. Detzler, A. S. Doria

PP-MO-519 BONE QUALITY IN PATIENTS WITH HAEMOPHILIA EVALUATED BY QUANTITATIVE ULTRASOUND
A. Boban* (HR), D. Kastelan, S. Zupancic-Salek

PP-MO-520 ALLELIC VARIANTS OF HUMAN FACTOR VIII IN BRAZILIAN PATIENTS WITH SEVERE HEMOPHILIA A AND CORRELATION WITH THE RISK OF INHIBITOR
A. Santos* (BR), G. Damian, L. H. Siqueira, E. V. de Paula, J. M. Annichino-Bizzacchi, M. C. Ozelo

PP-MO-521 LOWER INCIDENCE OF IGGS SUBCLASSES OF ANTI-FVIII ANTIBODIES THAT RECOGNIZE AN INTERMEDIATE-PURITY PLASMA DERIVED FACTOR VIII PRODUCT IN SEVERE HEMOPHILIA A INHIBITOR POSITIVE PATIENTS
A. Santos* (BR), S. A. L. Montalvão, L. H. Siqueira, G. B. Damian, S. Thomas, M. Veiga, D. E. Fujimoto, A. Streva, E. V. de Paula, J. M. Anicchino-Bizzacchi, M. C. Ozelo

PP-MO-522 CARDIOVASCULAR DISEASE IN PATIENTS WITH HEMOPHILIA B
A. A. Sharathkumar* (US), M. Soucie, B. Trawinski, A. Griest, A. Shapiro

PP-MO-523 INHERITED BLEEDING DISORDERS: THE EMILIA ROMAGNA REGION REGISTRY, 2008 UPDATE A. Tagliaferri* (IT), G. Rivolta, C. di Perna, C. Biasoli, L. Valdrè, G. Rodorigo, M. D’Incà, M. Serino, S. Macchi, D. Vincenzi, P. Pedrazzi, M. Arbasi, F. Riccardi, C. Pattacini

PP-MO-524 COMPARISON OF THREE DIFFERENT THROMBIN GENERATION ASSAYS IN PATIENTS WITH HAEMOPHILIA
S. Aghighi, A. F. Riddell* (UK), P. Chowdary, A. Gatt

PP-MO-525 MANAGEMENT OF ACUTE CORONARY SYNDROMES IN HAEMOPHILIACS: A NEW CHALLENGE BETWEEN HAEMORRHAGIC AND THROMBOTIC RISK
A. Coppola* (IT), G. F. Rivolta, M. Lapecorella, A. C. Molinari, C. Santoro, M. di Capua, M. N. . di Minno, L. Banov, C. di Perna, E. Zanon, P. Schinco, R. Santoro, A. Tagliaferri

PP-MO-526 MULTIDISCIPLINARY APPROACH FOR OPTIMIZATION OF HAEMOPHILIA CARE IN VENEZUELA
A. Ruiz-Saez* (VE), A. Boadas, A. Arguello, N. de Bosch, A. Luque, C. Garrido

PP-MO-527 VARIABLE IMMUNE RESPONSE IN TWO BROTHERS WITH MILD/MODERATE HEMOPHILIA A CARRYING THE ARG2150HIS SUBSTITUTION
B. Fimbel* (FR), S. Regina, C. Pouplard, G. Lavigne-Lissalde, R. D’Oiron, Y. Gruel

PP-MO-528 SPORADIC VERSUS FAMILIAR SEVERE HAEMOPHILIA A RATIO IN A NEONATE COHORT
C. Altisent* (ES), F. Vidal, L. Ramirez, M. Martorell, I. Corrales, R. Parra

PP-MO-529 DUPLICATION OF EXONS 1 TO 22 OF THE F8 GENE: À PROPOS OF A HAEMOHILIA A PATIENT
C. Costa* (FR), E. Bieth, P. Boisseau, S. Letourneau, F. Dastot, E. Girodon, M. Goossens

PP-MO-530 THE FRENCH BLOOD PRODUCTS SUPPLY DATABASE (MDSRAPPRO): AN EFFECTIVE TOOL FOR LONG-TERM NATIONAL SURVEILLANCE OF COAGULATION FACTORS AND MANAGEMENT OF SUPPLY SHORTAGES A COORDINATION BETWEEN PHARMACISTS, PHYSICIANS, PATIENTS ASSOCIATION, HEALTH AUTHORITI
P. Chocarne, M. Gensbittel, V. Chamouard, C. Rothschild, J. Goudemand, S. Clayessens, N. Ferré, B. Worms, J. Vernois, C. Vigneron, P. Arnaud, F. Suzan, C. Ratignier* (FR)

PP-MO-531 CARRIER AND PRENATAL DIAGNOSIS OF HEAMOPHILIA IN CHINESE PEDIGREE
D. Jing* (CN), Y. Lu, Q. Ding, H. Wang, X. Wang

PP-MO-532 MULTICENTRIC SELF-ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN ROMANIAN HAEMOPHILIACS, USING EQ-5D
D. Lighezan* (RO), M. Mihailov, L. Pop, L. Ritli, C. Jinca, P. Stancu, A. Cucuianu, D. Baghiu, G. Olteanu, A. Lacatusu, E. Ursu, W. Schramm, M. Serban

PP-MO-533 DIFFERENTIAL EFFECT OF PROPHYLACTIC OR ON DEMAND TREATMENT REGIMES IN HEMOPHILIA A PATIENTS ON TAFI ACTIVATION
D. Mikovic* (RS), M. Holmström, B. J. Woodhams, J. Antovic

PP-MO-534 THE UK NEQAS GENETICS QA SCHEME FOR INHERITED BLEEDING DISORDERS
D. J. Perry* (UK), T. Cumming, S. Kitchen, I. Jennings, A. Goodeve, M. Hill, I. Walker

PP-MO-535 PATTERNS OF BLEEDING IN CONGENITAL HEMOPHILIA PATIENTS WITH INHIBITORS AND VERY FREQUENT BLEEDING: ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY
E. J. Neufeld* (US), D. L. Cooper

PP-MO-536 MOLECULAR ANALYSIS OF HEMOPHILIA A IN MURCIA, SPAIN
F. García Candel* (ES), E. Tizzano, M. Moreno, E. Salido, M. Majado, J. Moraleda, C. Funes, A. Morales

PP-MO-537 THE RELATIONSHIP BETWEEN FACTOR LEVELS RADIOLOGICAL SCORE AND ACTIVE LIFE OF 14 PATIENTS WITH HEMOPHILIAC ARTHROPATHY
S. Guler, F. Pekun, E. Turkkan* (TR), G. Korkmaz

PP-MO-538 A SERIES OF HEREDITARY FACTOR DEFICIENCIES PRESENTING WITH BLEEDING AT A PEDIATRIC HEMATOLOGY UNIT
F. Pekun, E. Turkkan* (TR), S. Guler, G. Korkmaz

PP-MO-539 12 NOVEL FACTOR IX MUTATIONS IDENTIFIED IN IRANIAN HAEMOPHILIA B PATIENTS
G. Rastegarlari* (IR), M. Rassoulzadegan, S. Ravanbod, S. Hejazi, S. Enayat, F. A. Ala

PP-MO-540 IMPACT ON THROMBIN GENERATION OF DIFFERENT FACTOR VIII CONCENTRATES IN PATIENTS WITH ACQUIRED HAEMOPHILIA
G. Salvagno* (IT), J. Astermark, M. Gunnarsson, M. Franchini, G. Poli, G. Guidi, G. Lippi, E. Berntorp

PP-MO-541 A PHARMACOKINETIC STUDY: IMPACT ON THROMBIN GENERATION OF TWO RECOMBINANT FACTOR VIII CONCENTRATES IN SUBJECTS WITH HAEMOPHILIA A
G. Salvagno* (IT), J. Astermark, M. Ekman, M. Franchini, G. Guidi, G. Lippi, R. Janco, E. Berntorp

PP-MO-542 COMPARISON OF THE RATES OF JOINT ARTHROPLASTY IN PATIENTS WITH SEVERE FACTOR VIII AND IX DEFICIENCY: AN INDEX OF DIFFERENT CLINICAL SEVERITY OF THE TWO COAGULATION DISORDERS
G. Tagariello* (IT), A. Iorio, E. Santagostino, M. Morfini, R. Bisson, M. Innocenti, M. Mancuso, M. Mazzucconi, G. Pasta, P. Radossi, G. Rodorigo, C. Santoro, R. Sartori, A. Scaraggi, L. Solimeno, P. Mannucci

PP-MO-543 HEPATITIS C IN HAEMOPHILIA – PREDICTIVE VALUES OF COAGULATION FACTOR ACTIVITIES IN PREDICTION OF FIBROSCAN VERIFIED CIRRHOSIS
G. Thomson* (UK), S. Trenchfield, D. Bevan, G. Moore, J. Ingerslev, S. Rangarajan, B. Sørensen

PP-MO-544 THROMBIN GENERATION: A COMPARISON OF ASSAYS USING PLATELET-POOR AND –RICH PLASMA SAMPLES FROM HEALTHY CONTROLS AND PATIENTS WITH HEMOPHILIA
G. R. Lischetzki* (DE), H. Topf, M. Rauh

PP-MO-545 PRELIMINARY EVALUATION OF DAILY QOL ASSESSMENTS IN CONGENTIAL HEMOPHILIA PATIENTS WITH ALLOANTIBODY INHIBITORS
G. A. Young* (US), C. T. Wilke, D. L. Cooper, A. Pickard

PP-MO-546 IDENTIFICATION AND CHARACTERIZATION OF A NOVEL ADENINE TO GUANINE TRANSITION IN INTRON 10 OF THE FACTOR VIII GENE AS A CANDIDATE CAUSATIVE MUTATION OF MILD HEMOPHILIA A
H. Inaba* (JP), T. Koyama, K. Shinozawa, K. Fukutake

PP-MO-547 SUCCESSFUL LIVER TRANSPLANTATION IN A PATIENT WITH MILD HAEMOPHILIA A AND LOW-TITRE OF FACTOR VIII INHIBITOR TREATED WITH RECOMBINANT FACTOR VIIa: THE FIRST ARGENTINIAN CASE STUDIED
H. A. Guglielmone* (AR), S. Minoldo, G. Jarchum

PP-MO-548 ALL ROUND UTILITY OF FACTOR VIII DEFICIENT PLASMA WITH VWF
J. Xia* (US), H. Patel, C. Kung, M. Triscott

PP-MO-549 UTILITY OF THROMBIN GENERATION IN SCREENING PATIENTS WITH HEMOPHILIA FACTOR DEFICIENCIES
J. R. Wu* (US), T. S. Smith, B. Bai

PP-MO-550 THE ROLE OF FIBROSCAN IN THE INVESTIGATION OF LIVER FIBROSIS IN HAEMOPHILIACS WITH CHRONIC HEPATITIS C VIRUS
S. Green, J. Vowles, D. Sheridan, M. L. Schmid, K. L. Talks* (UK)

PP-MO-551 FIRST EXPERIENCES WITH THE MEASUREMENT OF THROMBIN GENERATION(TGA) ON THE CEVERON®ALPHA IN THE ROUTINE LAB
L. Wagner* (AT), R. Luddington, A. Grigorov, L. Wiens, I. Hrachovinova, B. R. Binder

PP-MO-552 PREVALENCE AND MANAGEMENT OF INHERITED BLEEDING DISORDERS IN IRAN
M. Lak* (IR), R. A. Sharifian, M. R. Baghaiepour, H. Mansouritorghabeh

PP-MO-553 HEALTH-RELATED QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY COAGULOPATHIES
P. A. Vorobyev, O. V. Borisenko, U. A. Zhulev, N. I. Zozulya* (RU), K. G. Kopylov, E. A. Telnova, A. A. Tonoyan

PP-MO-554 SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII FOR THE TREATMENT OF PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A IN CHINA
R. Yang* (CN), Y. Zhao, J. Sun, J. Wu, X. Wang, M. Yu

PP-MO-555 GENETIC DEFECT ANALYSIS OF 104 HEMOPHILIA A PATIENTS IN TAIWAN
Y. Chen* (TW), T. Chao, S. Hu, S. Cheng

PP-MO-556 PRION REDUCTION BY THE MANUFACTURING PROCESS OF A VWF/FVIII PRODUCT DEMONSTRATED BY BIOASSAY AND BIOCHEMICAL ASSAY
A. Gröner* (DE), A. Buschmann, S. Rehberg, M. Groschup, W. Schäfer

PP-MO-557 MANUFACTURING PROCESSES OF PLASMA-DERIVED PRODUCTS REMOVE PRIONS
A. Gröner* (DE), W. Schäfer